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Abstract
Intracellular bacterial pathogens are hard to treat because of the inability of conventional
antimicrobial agents belonging to widely used classes, like aminoglycosides and β-lac‐
tams, fluoroquinolones, or macrolides to penetrate, accumulate, or be retained in the
mammalian cells. The increasing problem of antibiotic resistance complicates more the
treatment of the diseases caused by these agents. In many cases, the increase in therapeu‐
tic doses and treatment duration is accompanied by the occurrence of severe side effects.
Taking into account the huge financial investment associated with bringing a new antibi‐
otic to the market and the limited lifetime of antibiotics, the design of drug delivery sys‐
tems to enable the targeting of antibiotics inside the cells, to improve their activity in
different intracellular niches at different pH and oxygen concentrations, and to achieve a
reduced dosage and frequency of administration could represent a prudent choice. An
ideal drug delivery system should possess several properties, such as antimicrobial activ‐
ity, biodegradability, and biocompatibility, making it suitable for use in biomedical and
pharmaceutical formulations. This approach will allow reviving old antibiotics rendered
useless by resistance or toxicity, rescuing the last line therapy antibiotics by increasing
the therapeutic index, widening the antimicrobial spectrum of antibiotics scaffolds that
failed due to membrane permeability problems, and thus reducing the gap between in‐
creasingly drug-resistant pathogens and the development of new antibiotics. Different
improved drug carriers have been developed for treating intracellular pathogens, includ‐
ing antibiotics loaded into liposomes, microspheres, polymeric carriers, and nanoplexes.
The purpose of this chapter is to present the limitations of each class of antibiotics in tar‐
geting intracellular pathogens and the main research directions for the development of
drug delivery systems for the intracellular release of antibiotics.
Keywords: Intracellular bacterial pathogens, drug delivery systems, drug carriers, lipo‐
somes, polymeric carriers, nanoplexes
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1. Introduction
Infections with intracellular bacterial pathogens are hard to treat due to the inability of
conventional antimicrobial agents to penetrate, accumulate, or be retained in the mammalian
cells [1]. The increasing problem of antibiotic resistance complicates more the treatment of the
diseases caused by these agents.
Taking into account the huge financial investment associated with bringing a new antibiotic
to the market and the limited lifetime of antibiotics, the design of drug delivery systems to
enable the targeting of antibiotics inside the cells, to improve their activity in different
intracellular niches at different pH and oxygen concentrations, and to achieve a reduced
dosage and frequency of administration could represent a prudent choice [2]. This approach
will allow reviving old antibiotics rendered useless by resistance or toxicity, rescuing the last
line therapy antibiotics by increasing the therapeutic index, widening the antimicrobial
spectrum of antibiotics scaffolds that failed due to membrane permeability problems, and thus
reducing the gap between increasingly drug-resistant pathogens and the development of new
antibiotics.
The purpose of this review is to present the limitations of each class of antibiotics in targeting
intracellular pathogens and the main research directions for the development of drug delivery
systems for the intracellular release of antibiotics.
2. Microbial adaptation to the intracellular lifestyle
Invasion (aggressiveness or invasiveness) represents the ability of pathogens to overcome
epithelial barriers through specific mechanisms, to penetrate the host tissue, and to multiply,
producing pathological effects [3]. Invasive microorganisms have the ability to penetrate into
the host tissues or to stimulate the endocytic function of the substrate and to maintain their
viability in the host cell [4].
Many pathogenic bacteria are capable of surviving inside eukaryotic, normally nonphagocytic
cells (mucosal cells and blood vessel endothelial cells) [5, 6]. The intracellular medium offers
protection to the microorganisms that could thereby multiply or persist [7].
Some pathogenic bacteria are facultative intracellular (e.g., Mycobacterium spp., Listeria
monocytogenes, and Salmonella spp.) going through an intracellular phase during infectious
cycle without being strictly dependent on the cellular medium, while others are obligate
intracellular parasites (Chlamydia spp. and Rickettsia spp.), which do not survive in the
extracellular medium of the host. They infect endothelial and epithelial cells and also mono‐
cytes.
Generally, invasive organisms adhere to the host cells using a class of molecules represented
by proteins with adhesion function associated to the cell surface called invasins, which direct
the entry of the bacteria into the cells [8]. The mechanisms of adherence trigger or promote
cellular signals, which directly or indirectly facilitate the bacterial penetration [9].
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After bacterial adherence, invasion is produced in two ways: (a) the “zipper” mechanism—
after binding to the host cell, the adherent bacteria induce changes of the cytoskeleton, in
particular, actin filaments, resulting in the embedding of the bacteria, and (b) internalization
by a pathway independent of the membrane molecules that mediate adherence. In this case,
the interaction of the bacteria with the host cell membrane produces localized intrusion
(ruffling), followed by endocytosis [10].
Professional phagocytes express membrane receptors for conserved structures of the microbial
pathogens called pathogen-associated microbial patterns (PAMP), which are missing from
mammalian cells. The broad spectrum of microbial pathogens is therefore recognized by a
limited number of receptor molecules of the host (pathogen recognition receptors [PRR])
belonging to the following groups: receptors of TLR family (Toll-like receptors), which recognize
different structures of the microorganisms—glycoproteins, lipoproteins, heat shock proteins,
and flagellar proteins; lectin-type receptors with specificity for common carbohydrates
expressed on the surface of bacteria, i.e.: (a) receptors for mannose (MBL) that could also
recognize other carbohydrates (N-acetylglucosamine, glucose, and L-fucose), (b) receptors for
galactose recognizing N-acetyl-galactosamine and galactose, (c) receptors for fucose and
specific membrane molecules, such as CD14 with specificity for glycolipids (LPS) and for the
lipoarabinomannans (LAM) of mycobacteria.
The fact that adhesion of bacteria to eukaryotic cells requires the recognition of specific
oligosaccharides or glycoproteins [11] was demonstrated by the in vitro experimental results,
showing that oligosaccharides are the most potent inhibitors of the interaction between the
bacteria and the eukaryotic cell surface.
Invasion is an active event, sustained by normal cell functions [12], with the host cell cytoske‐
leton supporting the invasion and embedding process [13].
Pathogenic bacteria, such as L. monocytogenes, Shigella spp., and Rickettsia spp., possess
mechanisms that induce cytoskeletal rearrangements (actin condensation with the formation
of a propulsion actin comet behind the bacterial cells) of the host cell to assure their cytoplas‐
matic and intercellular transit [13].
Some bacterial strains could modulate the host cell apoptosis during the infectious cycle [14].
This proapoptotic effect could facilitate the endocytosis of the apoptotic bodies containing
bacterial cells by the adjacent cells, without the occurrence of an inflammatory process, but
bacteria could spread into the healthy tissues at the same time. The bacteria-induced apoptosis
is mediated by the activation of caspases or Fas/FasL pathways correlated with the inactivation
of antiapoptotic proteins (e.g., NFkB and MAP kinases). Pseudomonas aeruginosa could induce
the lung epithelial cells apoptosis, a process by which the bacterial cells are cleared from the
lung or other infected organs. However, P. aeruginosa could invade, survive, and multiply in
the host cells and induce an antiapoptotic effect in order to maintain its host and protect itself
from the immune response effectors [15].
By using microscopy evaluation and viable cells count assays, we have demonstrated that P.
aeruginosa clinical strains could survive and multiply in nonphagocytic epithelial cells [5],
inducing changes of cellular morphology (cytoplasm wrinkling, the formation of long, lamellar
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pseudopodes). The respective P. aeruginosa strains were also able to modulate the apoptosis
of the infected cells by increasing the expression of the proapoptotic caspase 3 and Bax genes
and by decreasing the expression level of the antiapoptotic Bcl-2 and Mcl-1genes [16].
Selective adherence to the microfold (M) cells is an effective way of invasion. Bacteria and
viruses that use M cells transport pathways can infect the gastrointestinal mucosa and may
disseminate systemically.
M cells, which cover the Peyer’s patches, separate the epithelium-associated lymphoid follicles
from the gut lumen. They are coated with a thin mucous layer, have short microvilli, but are
very active in terms of pinocytosis compared with columnar epithelial cells. The Peyer’s
patches, consisting of aggregated lymphoid follicles, are the major component of the mucosal
immune system and have a precise function: to exclude exogenous antigens, before they enter
into the internal medium, and to avoid or minimize the exposure of the systemic immune
apparatus to molecular antigens or cells that reach the internal medium. At the same time,
mucosa-associated lymphoid tissue (MALT) should remain insensitive to normal mucosal
microbiota. MALT is therefore a “control zone” of the body in contact with antigens and also
has a regulatory role on the functionality of systemic immune response. This explains the fact
that oral administration of an antigen in human or animals, in essence, does not produce a
systemic immune response, but typically a mucosal immune response. The mechanism is
unknown, but the mucosal immune system prevents an extensive immune response after the
contact with a large number of intestinal antigens, especially with food origin. Bacterial or viral
complex antigens can initiate a complex immune response through mucosal immune appara‐
tus. MALT functional deficiencies expose the organism and systemic immune apparatus to a
permanent state of activation, which exceeds the physiological limits, with the possible
occurrence of autoimmune diseases [17].
M cells can uptake by pinocytosis soluble luminal material and transfer it to the underlying
macrophages. Macrophages process the antigens and present them to the adjacent lympho‐
cytes. They have few lysosomes, and the embedded materials are not submitted to degrada‐
tion. M cells are carrying macromolecules, particles, and microorganisms directly into the
cellular environment of the mucosal lymphoid follicles.
M cells have no receptors for polymeric immunoglobulins, indicating that they do not transfer
IgA, which favors the access of the antigens to the mucosal surface. They are specialized for
the transepithelial transport. The basolateral surface of M cells is deeply intrusive, presenting
extensions of about 10-µm dimension, which are forming a big intraepithelial “pocket” and
extending in the underlying lymphoid tissue, in which transported macromolecules and
particles are released. Below the epithelial M cells, there is a rich population of macrophages
and dendritic cells in close spatial relationship with CD4 T cells harboring the αβ type receptor
and B cells. Few lymphocytes are memory T cells or uncommitted (naive) cells. The folds of
M cell are the site of interaction between T cells and antigen-presenting cells (B cells and
macrophages).
Through follicular epithelium, microorganisms gain access to the lymphoid follicle structures.
The consequence is beneficial because it initiates protective immune response against luminal
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microorganisms. M cells are therefore regarded as an early warning system of the immune
system. Although M cells have evolved as a strategic protective system, their functional
properties are qualifying them as true gateways—the Achilles heel of the intestine, because
the pathogenic bacteria could gain in this way access to deeper structures.
The bacterial cells interact with M cells, probably via carbohydrates [18]. M cells possess a wide
range of glycoconjugates that modulate their capacity to uptake microorganisms [19]. Further,
macrophages and dendritic are involved in the embedding pathogens transported by M cells,
in processing and storing antigens [20].
Certain Escherichia coli pathogenic strains that colonize the intestinal mucosa could selectively
adhere to the epithelial cells and interact with the M cells. The adherence to intestinal epithelial
cells and to M cells induces the disintegration of the microvilli and M cells folds and also the
appearance of some special structures called pedestals—a consequence of actin filaments
reorganization at the adhesion site [21].
Shigella sp., a facultative intracellular pathogen induces severe damages of the small intestine
and colon mucosa, accompanied by the loss of epithelial barrier function. Shigella sp. cells
adhere to the cellular membrane, are phagocytosed and released into the cytoplasm after the
degradation of the phagosome membrane, where they multiply, induce the assembly of a tail
of actin filaments, and are eliminated in a vacuole with membranar origin, which is subse‐
quently phagocytosed by the neighboring cells [22].
In vitro experiments with enterocytes have shown that Shigella flexneri does not invade the
apical surface, if the epithelial tight junctions are intact. The invasion is possible only through
the basolateral membrane. In vivo, Shigella invades the mucosa, first of all, through M cells,
followed by the invasion of epithelial cells through the basolateral surface. Mucosal ulcerations
have the highest frequency in the ileum and colon, where lymphoid follicles and M cells are
more numerous. We have demonstrated that S. flexneri and S. boydii strains modulated the
expression of different anti- and proinflammatory cytokines in HeLa cells, by decreasing the
production of IL-1β, IL-6, TNF-α, and IL-17 [22, 23].
Studies on the relationship between viral and bacterial infections showed that the immunity
of host organism is reduced temporarily in the context of viral infections, increasing the
incidence of bacterial infections, probably by increasing the level of expression of epithelial
cell receptors for bacterial adhesins. Virus-infected host cells could also undertake changes of
the cytoskeleton [24], which may result in the increase/decrease of the bacterial invasion
capacity. Therefore, we have investigated the influence of viral preinfection using vaccinia,
measles, echovirus 32, and herpes simplex virus 1 strains on the ability of an enteroinvasive
E. coli strain to colonize the HeLa cells, and we have demonstrated that the viral preinfection
of the cellular substrate induced a decrease of the invasive ability, pleading for an increased
incidence of infections with extracellular pathogenic organisms after viral infections [6].
In the small intestine, Vibrio cholerae expresses a group of pilliary adhesins used for the
adherence to the enterocytes. The pilli maintain the vibrions adhered on the surface of the
mucosa, and the cholera toxin induces the secretion of chloride ions from the intestinal cells
into the lumen. V. cholerae also interacts closely with extensive areas of the apical membrane
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of the M cells. The activating signal induces actin reorganization, and bacterial cell is phago‐
cytosed, without the M cell damaging. However, bacteria embedding in the M cells does not
cause the disease in this case [25], but on the contrary, the process activates a protective immune
response of the mucosa, mediated by the secretion of anti-toxin and anti-LPS sIgA, which can
prevent mucosal colonization by V. cholerae and by default, prevent diarrheal disease.
The ingestion of Salmonella cells induces the infection of Peyer’s patches. S. typhi and S.
typhimurium adhere rapidly and selectively to M cells and also directly invade through
epithelium villi. Salmonella sp. cells are embedded in a large endocytic vacuole by a phagocy‐
tosis mechanism induced after apical microvilli disassembling and cytoskeleton reorganiza‐
tion.
The experiments with the ligated intestinal loops showed that after 30 min of injection,
Salmonella sp. cells induce the growth of M cells volume; and a rapid incorporation of the
bacteria was observed, followed by the degeneration of M cells and the access of the infectious
cells to the mucosa structure.
Yersinia sp. cells penetrate the intestinal mucosa through M cells to which bacteria adhere
preferentially, being embedded and crossing the cytoplasm by transcytosis.
A few bacterial species are able to force the entrance directly into the host cells, after adherence,
by the local enzymatic digestion of the host cell membrane. For example, Rickettsia prowazekii
secretes phospholipases that determine the localized and controlled degradation of the host
cell membrane. Through the membrane lesions, the pathogen enters directly into the cyto‐
plasm [26].
Most bacteria, including many pathogenic bacteria, are killed after their phagocytosis by
macrophages or neutrophils (PMNN). Some other species have developed some strategies that
allow them to survive and multiply inside phagocytes. S. flexneri, L. monocytogenes, and
Rickettsia sp. dissolve the initial membrane vacuole and thus gain access to the cytoplasm rich
in nutrients. Salmonella spp., Mycobacterium spp., and Legionella spp. could inhibit the fusion
between phagosome and lysosome and thus escape phagocytosis.
The virulence factors that determine the bacterial resistance to lysosomal enzymes and increase
the intracellular survival capacity are cell surface protective envelopes (capsule and LPS),
bacterial enzymes that neutralize the toxic free radicals and reactive oxygen species, and
proteolytic enzymes that degrade the lysosomal enzymes of the host [13].
3. Efficiency of different classes of antibiotics against intracellular
pathogens
Antibiotics  are  low  molecular  weight  substances  produced  by  microbial  biosynthetic
processes or by chemical synthesis, which can be used in low concentrations to specifical‐
ly inhibit the proliferation or to kill microorganisms [27]. Because of their high specificity,
antibiotics  exhibit  different  efficiencies  against  various  microbial  species.  Antimicrobial
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drugs act by different mechanisms, such as inhibition of cell wall synthesis, inhibition of
cell membrane functions, inhibition of protein synthesis at different stages (translation or
transcription), inhibition of nucleic acid synthesis, and blockage of metabolic pathways by
competitive inhibition (Figure 1) [28].
Depending on the number and diversity of  affected microbial  species,  the activity spec‐
trum of the antibiotics  can be broad (i.e.,  the spectrum of tetracycline is  represented by
Gram-negative  bacteria,  including  Chlamydia  sp.  and  Rickettsia  sp.  and  Gram-positive
species;  penicillins  are  active  especially  against  Gram-positive  species,  and some Gram-
negative  bacteria,  including  Chlamydia  sp.,  nitrofurans,  rifampin,  and  sulfonamides  are
active on a large number of  Gram-positive and Gram-negative bacteria species),  narrow
(novobiocin is active on Gram-positive bacteria, especially staphylococci, but also on Gram-
negative species, such as Haemophilus sp. and Pasteurella sp., glycopeptides and bacitracin
are  active  against  Gram-positive  bacteria),  and  limited  (nitroimidazoles  are  active  only
against anaerobic microorganisms).
Even within the same microbial species, there can be large differences regarding the suscept‐
ibility of different strains to a particular antibiotic; thus, antibiotic treatment in the clinical
setting requires the isolation of the microbial strain, which is the etiologic agent of a specific
infection (especially if it belongs to genera and species with a high ability of acquiring clinical
resistance) and determining its antibiotic susceptibility spectrum.
The in vivo antimicrobial activity is more complex, involving different host-related factors
along with the impact of the antibiotic and the nature of the antimicrobial agent. Thus, in the
host, a number of local factors (partial pressure of O2, pH etc.) could influence the activity of
the antibiotic. On the other hand, antibiotics are absorbed within the intestinal tract and
distributed unevenly in various tissues and body fluids, and very few reach active concentra‐
tions in the central nervous system (CNS) or inside most eukaryotic cells. It is also very difficult
to maintain an active concentration of the antibiotic for a prolonged period of time, so the
interval between doses should be rigorously respected. Some antibiotics have postantibiotic
effects (such as observed in the case of carbapenems activity against the Gram-negative bacilli)
and may modulate the inflammatory response by indirectly inducing the chronicity of
inflammatory reactions due to the accumulation of bacterial fragments. The combination of
two or more antimicrobials is recommended for the treatment of severe and chronic infections
to avoid the appearance of resistant mutants (i.e., tuberculosis) and also in mixed infections,
for obtaining a synergy of action and a strong bactericidal effect (i.e., beta lactams and
aminoglycosides, trimethoprim and sulfamethoxazole, amphotericin and flucytosine, beta-
lactamase inhibitors and beta-lactam antibiotics).
Some antibiotic classes, such as macrolides, fluoroquinolones, tetracyclines, and ansamycins,
are known to be active against obligate intracellular and facultative intracellular organisms,
while others, such as beta-lactams and aminoglycosides, show no or only a poor intracellular
activity. However, these antibiotics are active against facultative intracellular organisms,
including Mycobacterium tuberculosis.
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Figure 1. The main mechanisms of action and cellular targets of antibiotics within the bacterial cell.
3.1. Inhibition of cell wall synthesis
Peptidoglycan cell wall is a closed structure, composed by covalently linked units, which allow
the sequential addition of new units on the external side of the cytoplasmic membrane, while
the old units from the peptidoglycan’s structure are shifted outward and released by the action
of autolysins.
The synthesis of the peptidoglycan takes place in three stages: (i) low-molecular-weight-
soluble precursors (GlcAc UDP and UDP-MurNAc-L-Ala-D-Glu-mezoDap-D-Ala-D-Ala) are
synthesized in the cytoplasm; (ii) the nonnucleotide region of the previously synthesized
molecular precursor (intermediate N-acetyl glucosamine and N-acetyl muramic acid-penta‐
peptide) is attached to a lipid carrier, integrated in the membrane and subsequently modified
by adding GlcNAc and pentaglycine, resulting undecaprenol-pyrophosphate MurNac (L-Ala-
D-Gln [NH2 [Gly5] L-Lys-D-Ala-D-Ala]-[beta1-4]-GlcNac), that will be translocated across the
plasma membrane and serves as a substrate for a transglycosylation reaction, polymerizing
the bacterial glycan chains of the cell wall, to form a repetitive disaccharide (MurNac-
GlcNAc)n; and (iii) the subunits of the peptidoglycan are polymerized by their insertion in the
preexisting cell wall, by the reaction of transpeptidation, which takes place at the terminal D-
ala-D-ala residues.
The polymerization and cross-linking of the sugar tetrapeptide chains are catalyzed by
penicillin-binding protein enzymes (PBP), located in the cytoplasmic membrane and the
periplasmic space.
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Some antibacterial agents interfere with the early steps of the cell wall synthesis (vancomycin,
bacitracin, and cycloserine), while others (β-lactam antibiotics, penicillins, cephalosporins,
monobactams, and carbapenems) inhibit the last steps of peptidoglycan synthesis, such as the
formation of interpeptidic links, because these antibiotics have structural analogy with
terminal D-ala-D-ala dipeptide [29].
Glycopeptides (vancomycin and teicoplanin) inhibit the early stage of the peptidoglycan
synthesis by binding to the carboxy-terminal dipeptide D-Ala-D-Ala. It has been revealed that
vancomycin shows a slow uptake and modest accumulation into macrophages, especially in
the lysosomes compartment (up to eightfold in 24 h) [30, 31], while teicoplanin, a more
lipophilic compound, shows a more extensive and faster intracellular accumulation (40- to 60-
fold) [32, 33].
A newly investigated glycopeptide antibiotic called oritavancin (LY333328) proved to be
avidly accumulated by J774 and THP-1 macrophages and rat fibroblasts and to a lesser extent
by LLC-PK1 and Caco-2 cells. The intracellular pharmacokinetic and pharmacodynamic
results demonstrated that the level of accumulation reached a plateau (at 370-fold the extrac‐
ellular concentration) within 24 h, and the effect was partly defeated by a rise in serum protein
levels [34].
Bacitracin (a cyclic peptide) prevents the dephosphorylation of the lipid carrier molecule,
which transfers a newly synthesized peptidoglycan molecule to the cell membrane during the
synthesis of the cell wall. This antibiotic is toxic to kidneys and is not systemically administered
but is applied topically to treat skin and mucosa infections.
Cycloserine competitively inhibits the formation of D-ala from L-ala and thus stops the
synthesis of the dipeptide D-ala-D-ala. This antibiotic is relatively toxic and is used for the
treatment of M. tuberculosis infections resistant to other drugs.
Fosfomycin is a pyruvyl-transferase inhibitor, which blocks the synthesis of N-acetyl-muramic
acid.
Cycloserine and fosfomycin act as peptidoglycan precursor analogues. They are very hydro‐
philic molecules and enter the cytoplasm following the path of transport systems usually
utilized for some related metabolites; i.e., fosfomycin is structurally analogous to the phospho-
enol-pyruvate and cycloserine is similar to D-alanine.
Beta-lactam antibiotics act as pseudosubstrates and perform the acylation of the active sites of
the PBP transpeptidases, which are thus unable to catalyze the polymerization of the pepti‐
doglycan. The acylation reaction of the PBP is very slowly reversible. PBP-deacylated enzymes
are unable to catalyze the cross-linking of peptides (Figure 2). Antibiotic-PBP complexes
stimulate the release of autolysins, which produce the degradation of the cell wall, leading to
osmotic bacterial cell lysis.
The inhibitors of beta-lactamase enzymes, such as clavulanic acid, sulbactam, tazobactam,
have a high affinity for the respective antibiotic-inactivating enzymes, inducing their acylation
and formation of stable, unefficient complexes (Figure 3).
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Figure 3. Beta-lactamase enzymes inactivation by acylation in the presence of clavulanic acid.
Penicillin G is the drug of choice for meningococcal and gonococcal intracellular infections.
Third-generation cephalosporins (cefotaxime, ceftazidime, ceftriaxone, cefotetan, ceftizoxime,
cefoperazone, and cefixime) may cross the blood–brain barrier; therefore, cefotaxime, ceftriax‐
one, and ceftizoxime are usually intravenously administrated for the treatment of meningitis
caused by Gram-negative bacteria. The intracellular concentration of beta-lactams is usually
Figure 2. Beta-lactam antibiotics mediate the inactivation of PBP by the acylation reaction.
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lower than the extracellular amount, as revealed for both phagocytic and nonphagocytic cells
[35, 36]. This could be explained by the weak acidic character of these molecules affecting their
accumulation in acidic cytosol milieu [37].
3.2. Inhibition of the cytoplasmic membrane function
Cytoplasmic membrane acts as a selective permeability barrier for ions and nutrients and is
also the headquartered structural transport system that controls the chemical composition of
the cytoplasm. The disruption of structural integrity and/or functional parameters entails the
amendment of ion-selective permeability and loss of ionic or macromolecular balance.
Bacteria and fungi have a slightly different cellular membrane as compared with the animal
cells, this being injured faster by different therapeutic agents, which enables selective therapy.
Biological membranes are comprised of a lipid matrix, wherein the randomly distributed
globular proteins penetrate the lipid layer. Cationic, anionic, or neutral detergents may disrupt
biological membranes. The effect of polymyxins is similar to the cationic detergents. Their
molecule contains hydrophilic and hydrophobic groups. These antibiotics are positively
charged at neutral pH and actin similar with the cationic compounds, which are active against
the polyanionic outer membrane of Gram-negative bacteria (the load offered by the lipopoly‐
saccharide). Detergents (which are molecules containing lipophilic and hydrophilic group) act
by disorganizing the double lipid layer leading to cell disruption.
Polymyxins are polypeptide antibiotics (octapeptides of high molecular weight) with specific
chemical and biological properties. There are five known major chemically distinct polymyx‐
ins, designated as polymyxin A, B, C, D, and E. All polymyxins are synthesized by Bacillus
polymyxa and have the same antibacterial spectrum. Polymyxins A and D are nephrotoxic and
therefore cannot be used in vivo. The most representative are polymyxin B and colistin (or
polymyxin E), which are also the less cytotoxic (in concentrations up to 5 µg/ml), being most
active against Gram-negative bacteria, such as Brucella sp., Yersinia sp., Salmonella sp., Shigella
sp.), probably due to their negative lipid charge.
Polymyxins are not absorbed from the intestine, and also they do not accumulate in active
concentrations in soft tissues, being not efficient in the treatment of systemic or internal organs
infections. In exchange, they can be used for the treatment of superficial, cutaneous, or mucosal
infections (wounds, burns, intestinal tract mucosa, and pleural cavity infections), as well as for
the prophylaxis of transplant or digestive tract surgery. Polymyxins are used with great
effectiveness in the treatment of meningeal, lung, and urinary tract infections. They are often
associated with other antibiotics to extend the antimicrobial activity spectrum.
The fixation of the antibiotics within the membrane structure depends on the concentration of
divalent environmental cations: their deficiency or excess inhibits the action of polymyxins.
Also, the LPS composition, bacterial membrane phospholipids, and proteins influence the
sensitivity or resistance of various bacterial species to the action of polymyxins.
Polymyxin and other polycationic molecules bind to the lipid A of LPS in a stoichiometric ratio
and are inserted into the membrane structure. Such a molecular patchwork disorganizes the
lipid layers so that the cell membrane does not function normally as effective osmotic barrier.
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Due to structural deterioration of external and internal membranes, osmotic balance is
disrupted by the loss of K+ ions. The permeability changes are associated with the loss of soluble
cell constituents and viability. The mechanism is the same as that proposed for hemolysis by
the action of ionic detergents. The hemolytic effect occurs due to the disruption of cholesterol–
phospholipid–lipoprotein complex from the erythrocyte membrane. Other agents acting on
the cytoplasmic membrane are amphotericin B, imidazoles, and triazoles.
3.3. Inhibition of the protein synthesis
Several classes of antibiotics are active specifically on the 70S ribosomes, thus blocking protein
synthesis at different levels [38].
Aminoglycosides are low molecular weight cationic molecules, but very hydrophilic, which
accumulate in the cell only through an energy-dependent transport process. Their accumula‐
tion in the bacterial cell occurs through two phases: Phase I is slow and depends on the
transmembrane gradient of the electrical potential and thus the oxidative respiratory sinergon,
and phase II is quick and translates into an important intracellular accumulation. Intracellular
concentrations are approximately 100 times higher than those from the external environment.
Slow accumulation causes a bacteriostatic antibiotic, while rapid accumulation produces
bactericidal effects. The accumulation rate is conditioned by the size of the electric component
(Δψ) and the proton-motive force. This explains why microorganisms with transportation
systems deficiencies, such as anaerobes, are intrinsically resistant to aminoglycosides. For the
same reason, enterococci and other facultative anaerobes are resistant to low concentrations
of aminoglycosides [39].
An important role in the intracellular accumulation of aminoglycosides is attributed to the
periplasmic proteins whose synthesis is induced by the antibiotic.
Aminoglycosides induce the pleiotropism phenomenon (i.e., simultaneous changes in the
expression of many genes) and also produce mRNA reading errors.
Aminoglycosides are rapidly acting antibiotics with broad spectrum of action being active
against strict and facultative Gram-positive and negative aerobic bacteria.
Aminoglycosides could slowly accumulate through endocytosis in the lysosomes of the
eukaryotic cells to an apparent cellular-to-extracellular ratio of 2 to 4, excepting some tissues
like kidney proximal tubular cells, exhibiting binding sites such as megalin and acidic
phospholipids where the accumulation is faster [40–43].
Spectinomycin is an aminocyclitol antibiotic related to the aminoglycosides, manifesting
bacteriostatic action, usually used for the treatment of gonorrhea produced by penicillin-
resistant Neisseria gonorrhoeae strains.
The encapsulation of aminoglycosides in liposomes could increase the therapeutic index of the
drug by reducing the level of drug delivered at the sites where the antibiotic is toxic to the
therapeutic amounts necessary for the treatment of infection. This procedure also increases the
aminoglycosides efficiency against intracellular bacteria.
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Tetracyclines represent a family of antibiotics inhibitory for the protein synthesis through a
mechanism of blocking the attachment of aminoacyl–tRNA complex to the ribosome acceptor
site (site A) [44]. These antibiotics have a broad spectrum bacteriostatic effect, being active
against Gram-positive Gram-negative bacteria and protozoa, but they also kill normal gut
microbiota and produce gastrointestinal disorders.
Tetracyclines have the ability to accumulate in eukaryotic cells, including neutrophils [45].
Tetracyclines are strong chelating agents, their pharmacological properties being influenced
by the presence of metal ions. Each of the rings of the tetracycline core can contain only linear
carbon atoms in order to keep the antibiotic activity.
Atypical tetracyclines and some of their analogues disrupt the cytoplasmic membrane
structure and manifest a bactericidal effect, which contrasts with the bacteriostatic effect of
tetracyclines, reversibly inhibiting protein synthesis. Atypical effects of membrane disruption
are likely a consequence of the lipophilic nature of the molecule. Because of many side effects
derived from their nonspecific interaction with prokaryotic and eukaryotic cell membranes,
atypical tetracyclines present no current therapeutic interest.
The use of this antibiotic during pregnancy or in the first 5 years of life results in the defor‐
mation of the fetus skull bones and permanent teeth staining due to their ability to bind Ca2+.
In the 80s, before the emergence of resistant strains of N. gonorrhoeae, tetracycline was used to
treat sexually transmitted infections and is currently used in the treatment of non gonococcal
urethritis and chlamydial infections
Tetracycline resistance is widespread in Gram-positive cocci and is present also in Mycoplas‐
ma sp.
Although the main action of tetracycline is antibacterial, this antibiotic is also active against
protozoan parasites,  inhibiting Giardia lamblia,  Trichomonas vaginalis,  Entamoeba histolytica,
and Plasmodium falciparum. The effectiveness of tetracycline derivatives to parasitic protozoa
is correlated with the degree of penetration into the cell. The most effective are lipophilic
compounds  that  cross  quickly  the  cytoplasmic  membrane  (such  as  the  tiotetracycline
derivative).
Glicil-tetracyclines are represented by tigecycline, used to treat skin and abdominal infections.
The structural feature of tigecycline is the substitution in the position 9 of the tetracycline with
a glycine residue. These are broad-spectrum antibiotics against N. gonorrhoeae, Legionella
pneumophila, and also for fast growing non tubercular mycobacteria.
They are active agents to be used for the prophylaxis of malaria and strains of P. falciparum
resistant to specific chemotherapeutic agents.
Macrolides, lincosamides, and streptogramins (MLS) have a different chemical structure, but
they act in a similar manner on a variety of intracellular bacteria (e.g., Gram-positive, Gram-
negative cocci, Chlamydia spp., Mycoplasma spp., and Legionella spp.).
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MLSs prevent bacterial ribosomes to translate the RNA in two different ways, either by the
inhibition of translocation of peptidyl-tRNA from the acceptor site (A) and the peptidyl donor
site (P) or by inhibiting the initial steps of the assembly of the 50S ribosomal subunit.
Macrolides have a marked intracellular accumulation in almost all cells, explained by their
weak basic character favoring the accumulation in the acidic cytosol compartment, particularly
in the lysosomal apparatus, with a rate depending on the derivative structure, lower for
erythromycin and higher for those carrying two basic functions [46, 47].
Regarding their structure, macrolides are characterized by a multiunitar lactone ring with 12,
14, 15, or 16 carbon atoms, with few double bonds, which contain attached 1–3 glucidic residues
by glycosidic linkages.
Macrolides are active against Gram-positive and Gram-negative bacteria (Mycobacterium spp.,
Treponema pallidum, Mycoplasma pneumoniae, Chlamydia sp., Rickettsia sp.).
Novel molecules, such as azithromycin and clarithromycin, have a superior antibacterial
activity as compared with erythromycin because they have higher coefficients of intracellular
penetration and are more stable, being more easily absorbed and manifesting lower incidence
gastrointestinal side effects. Azithromycin is active against Mycoplasma spp. and Chlamydia
spp. Clarithromycin has significant antibacterial activity in vitro against mycobacteria.
Streptogramins are represented by two synergistic components (A and B). Similar with
macrolides and lincosamides, the A and B compounds of the streptogramin set at the ribosomal
subunit 50S, 23S, and to rRNA.
Lincomycin and clindamycin are macrolides, but many of their biological properties are similar
to erythromycin. They consist of an amino acid linked to an amino-sugar. Ketolides (telithro‐
mycin) are new chemical entities, characterized by the replacement of L-cladinose in the
erythronolide A ring, with a 3-keto function and the C11–C12 carbamate [48]. ABT 773
represents the latest generation of drugs, characterized by 3-keto group that substitutes the
sugar rest of the 3-cladinose from erythromycin and clarithromycin [49].
Oxazolidinones (eperezolid and linezolid) represent a unique class of synthetic antimicrobial
agents with a unique mechanism of action, which eliminates the risk of extending existing
resistance to the available antimicrobial agents. The oxazolidinones are inhibitors of ribosomal
protein synthesis in bacteria, preventing the formation of the 70S initiation complex compris‐
ing fMet RNA, mRNA, and the two ribosomal subunits.
Linezolid has a good in vitro activity against N. gonorrhoeae, N. meningitidis, and M. tuberculosis.
There are few studies showing the capacity of oxazolidinones (i.e., linezolid) to preferentially
and rapidly accumulate intracellularly (in concentrations 1.2 times higher than the extracel‐
lular ones within 20 min), both in human phagocytic (PMNs) and in nonphagocytic (McCoy)
cells. However, the efflux of the antibiotic is also very rapid, the great amount of the intracel‐
lular antibiotic being released in less than 2 min [50].
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Sulfonamides are synthetic chemotherapeutic agents, very similar to sulfanilamide (para-
amino-benzenesulfonamide). The bacteriostatic action of this antibiotic is due to the interfer‐
ence with the folic acid synthesis pathway.
The best known sulfonamides are sulfadiazine and sulfamethoxazole (cotrimoxazole). As
sulfonamides, para-aminosalicylic acid (APAS) and dapsone obtained by chemical synthesis
are competitive inhibitors for the para-aminobenzoic acid metabolism and inhibits the
synthesis of folic acid, being active against M. tuberculosis and Mycobacterium leprae.
The family of the diaminopyrimidine derivatives includes trimethoprim and tetroxoprim.
Trimethoprim is  an analog of  dihydrofolic  acid,  which competitively inhibits  dihydrofo‐
late reductase, an enzyme that converts dihydrofolate to the active cofactor—tetrahydrofol‐
ic acid [51].
The blockage of the same biosynthetic pathways sequence under the action of sulfonamides
and trimethoprim provides a high degree of synergistic activity against a broad spectrum of
microorganisms.
3.4. Chemotherapeutic agents acting by inhibiting DNA replication and transcription
Quinolones (also known as 4-quinolones) are the first antimicrobials produced synthetically
and form a family of compounds that resemble the core quinolinic existence.
Along with the β-lactam antibiotics and macrolide antibiotics, quinolones represent one of the
three major families of antimicrobial agents used in human therapy [52]. Nalidixic acid is an
intermediate for the synthesis of quinolones. Subsequently, quinolones have diversified by
introducing a fluorine (F) in position 6 and position 7 of a heterocyclic ring (piperazine,
pyrrolidine etc.), which generated fluoroquinolones.
Fluoroquinolones (norfloxacin, pefloxacin, ofloxacin, ciprofloxacin etc.) have a broad spectrum
of activity against intracellular bacteria, including Chlamydia sp., Rickettsia sp. and mycobac‐
teria. These molecules penetrate the bacterial cell by passive diffusion and act on specific
targets represented by topoisomerases: DNA gyrase (topoisomerase II) and topoisomerase IV,
probably inducing lethal effects such as bacterial DNA damage.
Rifampicin B is naturally synthesized, but in the recent years, the semisynthetic derivatives of
rifampicin are the most extensively used. Rifampicin belongs to a group consisting of an
aromatic chromophore, which is included in the aliphatic chain. It is associated with the B
subunit of DNA-dependent RNA polymerase, thus blocking transcription and RNA synthesis
initiation. The antibiotic is widely used in the combinatory therapy of tuberculosis.
It was demonstrated that quinone and hydroquinone forms of rifampin can accumulate in
PMNs from normal and chronic granulomatous disease individuals and be active against
intracellular staphylococci invading the chronic granulomatous disease PMN [53].
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3.5. Other synthetic chemotherapeutic agents
Nicotinic acid hydrazide (isoniazid, INH), introduced in the clinic before 1950, together with
rifampin, forms the basis of antituberculosis chemotherapy. Isoniazid is a nicotinamide
derivative. The mechanism of action is not known, but it influences the synthesis of lipids,
nucleic acids and mycolic acid from M. tuberculosis.
It is assumed that isoniazid is active by competing with pyridoxine (vitamin B6) necessary for
the growth of M. tuberculosis cells or by inhibiting mycolic acid synthesis. It is bactericidal to
the growing cells and has a bacteriostatic action against the cells that do not replicate. Together
with PASA and dapsone, isoniazid is used to treat infections with Mycobacterium sp.
Ethambutol, pyrazinamide, and ethionamide block the enzymatic reactions in the bacterial cell
because they are similar but not identical to bacterial vitamins.
Ethambutol inhibits arabinosyl chloride-transferase enzyme involved in the biosynthesis of
arabinogalactan and lipoarabinomannan. Other effects attributed to metabolic inhibition
action of ethambutol are RNA and phospholipids synthesis, inhibiting the transfer of mycolic
acids linked to arabinogalactans of the murine cell wall and also inhibiting the synthesis of
spermidine at early stage conversion of glucose into monosaccharides used for the synthesis
of parietal polysaccharides and peptidoglycan. It is a very specific and effective drug used in
association with isoniazid for tuberculosis treatment. It has a good bacteriostatic effect [54].
Pyrazinamide is a synthetic derivative of nicotinamide, which is metabolized to the pyrazino
acid, antibacterial active intermediary.
Ethionamide, a derivative of the isonicotinic acid, is active against M. tuberculosis and other
mycobacteria, acting through inhibition of mycolic acid synthesis.
Despite the massive amount of literature on the intracellular activity of antibiotics and on its
relation to cellular accumulation and disposition, the relationship between drug concentration
(or dosing), time of exposure (or other pertinent pharmacokinetic parameters), and chemo‐
therapeutic response (in terms of quantitative measurement of the variation in the bacterial
population) is incompletely elucidated [55]. Clinical studies, in this context, are particularly
difficult due to the complex extracellular and intracellular pharmacokinetic variables, micro‐
bial and host-response variables, and simultaneous presence of extracellular and intracellular
foci of infection. Some classes of antibiotics, such as ansamycins, macrolides, tetracyclines, and
fluoroquinolones, are generally considered as being active against intracellular pathogens,
being already clinically used for the treatment of bacterial infections with obligate and
facultative intracellular bacteria. Conversely, there is a consensus over the fact that beta-
lactams and aminoglycosides show no or only a poor intracellular activity. However, beta-
lactams could exhibit a time-dependent activity against intracellular bacteria when
administered in prolonged treatments at the maximal dose to compensate for the lack of
accumulation, whereas aminoglycosides, which are concentration-dependent, could be active
a high concentrations [56]. For macrolides, activity is clearly observed against phagosomal
organisms (phagosomes are neutral or only slightly acidic) at a sufficiently high concentration
to cope with the loss of activity caused by low pH or binding to cell constituents. Although
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some organisms, like Chlamydia sp. and Legionella sp., are quite sensitive, this may not be the
case for others, such as Staphylococcus aureus.
The balance between influx and efflux, metabolism, and binding properties determines the
intracellular concentration of free active drug; bacterial responsiveness, physico-chemical
conditions prevailing at the site of infection, and degree of cooperation (or hindrance) with the
host defenses are affecting the intracellular activity of antibiotics.
4. Antibiotics carriers for the intracellular delivery
Intracellular bacterial pathogens are hard to treat because of the inability of conventional
antimicrobial agents belonging to widely used classes to penetrate the lipidic membrane. They
accumulate in different compartments of the cells and face the limiting conditions of the
phagocytic cells, such as the lysosomal acidic pH and inactivating enzymes, low oxygen
pressure, etc. [57, 58], requiring the development of efficient delivery systems that could release
the antimicrobial agent intracellularly in active concentrations, thus increasing its effectiveness
while decreasing the required therapeutic doses, its systemic toxicity, and the probability of
selecting resistance [59–61].
Different improved drug carriers have been developed for treating intracellular pathogens,
including antibiotics loaded into liposomes and other lipid formulations, microspheres,
polymeric carriers, fullerenes, dendrimers and nanoplexes [1, 61–63].
The advantages of using drug delivery systems are represented by the tunable surface/size/
shape/functionalization properties, depending on the structure of the transported drug;
evasion of the immune system; use of the same carrier to transport more than one drugs;
improvement of the biodisponibility, biodistribution, and pharmacokinetics of the drugs;
availability of drug carriers for different administration routes; and low probability of selecting
resistance [64, 65].
This section will focus on drug delivery systems oriented toward treatment of intracellular
infections.
4.1. Polymeric drug carriers
Polymeric (both natural and synthetic) biodegradable and/or biocompatible matrixes, such as
poly (ε-caprolactone) (PCL), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA),
poly(γ-glutamic acid) (PGA), poly(L-lysine) alginate, gelatin, collagen, cellulose, albumin,
fibrin, dextran, pectin, chitosan, agar, agarose, and carrageenans, could be used to embed/
encapsulate/adsorb/conjugate a certain drug in order to protect it against enzymatic and
hydrolytic degradation [66–79] to control the rate of drug release with an optimal maintenance
of the biologically active drug level within therapeutic window [80, 81], to prevent toxicity, to
target drugs to the site of action, and to improve absorption, bioavailability, and therapeutic
efficacy [82, 83].
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The polymeric carrier systems could be classified in four different categories: diffusion
controlled (the drug is released by diffusion), chemically controlled (the drug molecules are
linked to a polymeric backbone often by means of a spacer molecule, being released inside the
host tissue by hydrolysis or by the enzymatic cleavage of the linkage between the polymer
carrier and the drug, by polymer biodegradation or by bioerosion), solvent activated (control‐
led by swelling or osmosis allowing the drug inside the system to diffuse outward), and
magnetically controlled (the polymer carrier is combined with magnetic microparticles of iron,
cobalt, and nickel, which could be oriented inside the body by an externally applied magnetic
field) [67, 84–87].
Responsive or smart polymers respond and modulate their properties in accordance with
different external parameters (e.g., UV/visible light, electric charges, electromagnetic radia‐
tion, temperature, pH, ionic strength, ionic or metallic interactions), leading to degradation,
drug release, dissolution/precipitation, swelling/collapsing, and formation of micelles and
vesicles [88, 89].
Particulated micro- and nanospheres and capsules prepared from natural polymers have been
synthesized by emulsion polymerization, solvent evaporation, ionic gelation, self-assembly,
nanoprecipitation, and supercritical fluid technology for drug delivery [90–92].
While microparticles are likely to remain in time at the injection place and can be engulfed
only by phagocytes, the smaller nanoparticles can diffuse from the injection place and cross
biological barriers, including the cellular membrane of different cell types [93, 94].
Nanoparticle-based drug delivery systems were applied in the treatment of different infectious
diseases with intracellular pathogens, such as acquired immune deficiency syndrome (AIDS),
malaria, and tuberculosis [95, 96]. Polymeric nanoparticles represent also a promising solution
for the local delivery of therapeutics to the central nervous system through the blood–brain
barrier [96, 97].
The polymeric micelles consisting of a hydrophilic shell and a drug-containing core were used
to incorporate extremely hydrophobic drugs, to assure prolonged drug circulation time, drug
stability, and escape from the reticuloendothelial system due to their nanometer size [98].
Nanoparticles formulated using biodegradable polymers have been also shown to enhance
the delivery of antibiotics intracellularly and to improve their effectiveness as revealed by the
reduced microbial burden.
In comparison with other delivery systems, natural polymers are generally safer and more
stable, easier to obtain, and offer better control over agent release [82, 99].
Dextran, a biodegradable, biocompatible, nonimmunogenic, and nonantigenic polymer of
bacterial origin, composed essentially of α-1,6-linked D-glucopyranose units [100], proved to
improve the activity of polar molecules such as penicillins, aminoglycosides, rifampicines, and
quinolones and to efficiently challenge the drug delivery into the infected cells in an active
form, leaving the host cells intact [101]. Dextran microspheres could act as macromolecular
carriers for the small molecules antibiotics and induce endocytosis of the drug by the target
cell via a specific receptor, followed by the subcellular distribution of the drug to sites where
the microbial cells are localized [102].
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Chitosan-dextran sulfate (CD) nanocapsules were assessed for their efficiency in delivering
ciprofloxacin or ceftriaxone drugs against Salmonella using a murine salmonellosis model. CD
nanocapsules proved to efficiently target and kill the intracellular pathogen at a significantly
lower dose, as compared to the free antibiotic, assuring also a more increased retention time
of ciprofloxacin in the blood and organs [103].
Cyclodextrin, a cyclic oligosaccharide consisting of six to eight glucopyranose units joined
by  α-(1  →  4)  glucosidic  linkages,  exhibits  an  internal  lipophilic  cavity,  which  can  be
complexed  with  hydrophobic  agents  [104],  improving  drug  solubility,  stability,  and
bioavailability [105, 106].
Hyaluronic acid, a linear anionic polysaccharide of animal or microbial origin, belonging to
the glycosaminoglycans family, consisting of alternating units of N-acetyl-D-glucosamine and
glucuronic acid, is a promising delivery vehicle for antibiotics [107].
Alginate nanoparticles increased the activity of rifampicin, isoniazid, pyrazinamide, and
ethambutol against M. turberculosis by assuring a higher drug payload and therapeutic efficacy
as well as an improved pharmacokinetic [96].
Some pathogens can survive for a prolonged period of time in the first-line anti-infective
defense cells represented by polymorphonuclear leukocytes (PMNs). The amorphous chitin
nanoparticles with a size of 350 ± 50 nm in diameter proved to achieve a sustained release of
rifampin till 72 h and significantly enhanced the drug accumulation into the intracellular
compartments of PMNs [108].
Synthetic polymers are preferentially used for the development of drug delivery systems due
to their excellent and tailor-made properties (biocompatibility; water compatibility; lack of
immunogenicity; optimal degradation time coinciding with their function; appropriate
mechanical properties in terms of toughness, flexibility, and swelling; generation of nontoxic
degradation products that can be easily resorbed or excreted; flexibility for chemical modifi‐
cation to get increased biocompatibility and to enlarge the variety of the loaded agent; they do
not need to be removed from the body being able to be degraded and excreted or resorbed;
the existence of FDA and European Medicine Agency approval for drug delivery systems for
parenteral administration; and protection of the loaded agent from degradation, assuring its
sustained and targeted release) [99, 109–114].
Amoxicillin-loaded PLGA microspheres successfully eliminated L. monocytogenes from vital
organs (kidney, spleen, and brain) and also increased the survival rate of treated animals in
comparison with the free antibiotic, suggesting the targeted delivery of the antibiotic to the
infected macrophages, as well as its sustained release over an prolonged period of time [115].
The PLGA nanoparticles proved to be efficient in encapsulating and releasing the rifampicin
drug, showing an initial burst followed by the sustained release of this primary tuberculostatic
agent [116, 117]. Also, rifampicin-loaded polybutylcyanoacrylate nanoparticles potentiated the
in vitro and in vivo activity of rifampin and ciprofloxacin against Mycobacterium avium due to
an effective delivery of drugs to macrophages [118, 119].
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Gentamicin-loaded PLGA nanoparticles have been obtained for the treatment of brucellosis,
proving to achieve high intracellular bactericidal activity of the antibiotic [120].
The PLGA microparticles proved efficient for the delivery of the antibacterial phosphorylcho‐
line and of the dietary antigen beta lactoglobulin in a mouse model, inducing protective
mucosal immunity against intestinal infection by S. typhimurium [121].
PLGA nanoparticles have been shown to efficiently accumulate in inclusions in both acutely
and persistently infected Chlamydia-infected cells, while the encapsulation of rifampin and
azithromycin antibiotics in PLGA nanoparticles enhanced the effectiveness of the antibiotics
in reducing microbial burden. The combination of rifampin and azithromycin was more
effective than the individual drugs [122].
Gentamicin  was  ion-paired  with  the  anionic  AOT  surfactant  to  obtain  a  hydrophobic
complex (GEN-AOT) that was formulated as a particulated material either by the precipita‐
tion method or by encapsulation into PLGA nanoparticles. The in vitro studies against the
intracellular  bacteria  Brucella  melitensis  demonstrated  that  the  bactericidal  activity  of
gentamicin was unmodified,  proving their  use for the treatment of  infections caused by
intracellular bacteria [123].
Rapamycin-loaded PLGA microparticles effectively released the active drug inside dendritic
cells, under intra-phagosomal (pH 5) and extracellular (pH 7.4) conditions [124].
Amoxicillin-bearing human serum albumin and, more evident, amoxicillin-dopped PLGA
microparticles proved to be efficient in combating L. monocytogenes infection in a mouse
experimental model, as revealed by the decreased bacterial burden in various organs and
reduced viable counts, the results clearly demonstrating that the respective microparticles
successfully target the infected macrophages [106].
Poly(isohexylcyanoacrylate) (PIHCA) nanospheres improved the activity of ampicillin against
S. typhimurium and L. monocytogenes, but the particles themselves exhibited also antimicrobial
activity [125, 126].
Ampicillin-encapsulated poly(isohexylcyanoacrylate) nanoparticles prove to be more efficient
than the free antibiotic against L. monocytogenes infecting mouse peritoneal macrophage, as
revealed by the more drastic decrease of viable cell counts. However, the nanoparticles acted
on the intracellular bacteria after a lag period of 6–9 h, probably due to a required period for
the degradation of the polymer [127].
Poly-lactide-co-glycolide (PLG) nanoparticles enhanced the bioavailability and pharmacody‐
namic properties of rifampicin, isoniazid, pyrazinamide, and ethambutol against M. turbercu‐
losis [128].
Amphiphilic, cationic polymers with an amino moiety, a low molecular weight, and short alkyl
chains designed to mimic the host secreted microbicidal peptides are considered promising
candidates for potent and highly selective antimicrobial agents (acting on microbial walls or
mitochondrial activity) with decreased risk to select resistance [129, 130].
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The polyketal nanoparticles formulated from the hydrophobic polymer poly(1,4-phenylenea‐
cetone dimethylene ketal) (PPADK) improved the activity of superoxide-dismutase to
scavenge reactive oxygen species produced by macrophages [131, 132].
Poly-butyl cyanoacryle proved to increase the efficiency of the moxifloxacin fluoroquinolone
against M. tuberculosis infecting the THP-1 cells [133].
Polyalkycyanoacrylate nanoparticles proved to improve the activity of ciprofloxacin and
colistin against S. typhimurium at the early stages of the infection in mice and/or in vitro models.
Ciprofloxacin-loaded nanoparticles induced a significant decrease of bacterial counts in the
liver whatever the stage of infection and the form used. However, none of the treatments were
able to sterilize the spleen or the liver. In the in vitro study, colistin was only active against
bacteria recovered during the early phase of infection, whereas ciprofloxacin exerted its
activity at all times postinfection [134].
Amphiphilic block copolymers could self-assemble, resulting in vesicles called polymersomes
[135]. Polymersomes of (poly[2-[methacryloyloxy]ethyl phosphorylcholine] [PMPC]–poly[2-
[diisopropylamino]ethyl methacrylate] [PDPA] block copolymers) proved to successfully
deliver metronidazole and doxycycline in Porphyromonas gingivalis-infected oral keratinocytes
significantly increasing their activity [136].
4.2. Liposomes
Liposomes are small spherical, uni- or multilamellar vesicles in which the central aqueous
cavities are surrounded by amphipatic molecules, being thus able to entrap both hydrophilic
and hydrophobic drugs [137]. After intravenous injections, liposomes are taken up by
macrophages in the liver and in the spleen, representing thus a promising option for fighting
infections due to facultative intracellular bacteria, parasites, or viruses [138].
The incorporation of different tuberculostatic agents in liposomes (such as ciprofloxacin) has
shown good antibacterial efficacy both in both macrophage cell lines and in animal tubercu‐
losis models [139, 140].
Streptomycin inclusion in phosphatidyl glycerol, phosphatidyl choline, and cholesterol-
containing liposomes showed an increased antimicrobial activity against Mycobacterium
avium [141].
The encapsulation of antibiotics in liposomes could represent a viable solution for the drug
penetration into the systemic circulation through the alveolar-capillary barrier, followed by
its accumulation in different organ tissues or for the direct administration to the lung [142].
Phosphatidylcholine, cholesterol, dicetylphosphate, O-steroyl amylopectin, and monosialo‐
gangliosides/distearylphosphatidylethanolamine-poly (ethylene glycol) 2000 liposomes have
been shown to act as a promising targeted delivery systems for isoniazid and rifampicin to the
lung in mice experimental model [143].
The liposomal encapsulation of membrane-impermeative antibiotics, like gentamicin is among
the most used approaches to achieve intracellular antibiotic delivery and therefore increase
the drug’s therapeutic activity against intracellular pathogens.
Antibiotic Drug Delivery Systems for the Intracellular Targeting of Bacterial Pathogens
http://dx.doi.org/10.5772/61327
325
Gentamicin, encapsulated in plurilamellar liposomal vesicles, proved to be active against
intracellular Brucella abortus infecting murine monocytes [144].
Gentamicin entrapped within stable multilamellar liposomes was used to treat mice orally
infected with Salmonella dublin and proved to achieve high and persistent (up to 10 days)
concentrations of gentamicin in the spleen, while bacterial counts in the lymph nodes de‐
creased. Also, gentamicin entrapped in liposomes was less toxic in mice than its free form
[145]. Ciprofloxacin encapsulation in dipalmitoylphosphatidylcholine, dipalmitoylphospha‐
tidylglycerol, and cholesterol containing liposomes also proved increased anti-Salmonella
dublin activity demonstrated by the decreased mortality of animals and good distribution of
liposomes to all areas of infection [145].
The encapsulation of ampicillin in liposomes reduced the L. monocytogenes viable counts in
mice peritoneal macrophages [146]. The DOPE (dioleoylphosphatidylethanolamine) lipo‐
somes, sensitive to pH proved to be efficient in the ampicillin uptake by the macrophages
infected with L. monocytogenes, correlated with an increase in the microbicidal activity. The
efficiency of this drug delivery system was also proven in an in vivo mouse infection model,
as revealed by the decrease of viable cell counts in the liver and spleen [147].
Liposomes, as well as nanoparticles coated with a lipid bilayer have been used to encapsulate
drugs for the passive transport through the blood–brain barrier due to the enhanced lipophilic
transport of drugs to the target tissues [148–150].
Streptomycin and doxycycline were entrapped into macromolecular nanoplexes with anionic
homo- and block copolymers enabling the simultaneous binding of both antibiotics into the
nanoplexes, which significantly reduced the B. melitensis load in the spleens and livers of the
infected mice [151].
It was demonstrated that gentamicin can be easily introduced into membrane vesicles of Gram-
negative pathogens that naturally bleb off the bacterium throughout its growth cycle and
delivered directly not only to other Gram-positive and Gram-negative pathogens but also to
mammalian cells [152].
4.3. Niosomes
Niosomes or nonionic surfactant vesicles are microscopic, spherical, uni- or multilamellar, and
polyhedral vesicles of 10–1000 nm formed by self-assembly of a mixture of cholesterol and a
single alkyl chain nonionic and nontoxic surfactant with subsequent hydration [153]. Nio‐
somes can be used for the delivery of hydrophilic, lipophilic, and amphiphilic drugs, irre‐
spective of their degree of solubility [153]. Niosomes improve the activity of isoniazid and
rifampicin against M. tuberculosis infecting the J774 macrophage cell line [154, 155].
4.4. Solid Lipid Nanoparticles (SLN)
Solid  lipid  nanoparticles  (SLN)  (50  nm–1  nm)  are  colloidal  carriers  for  lipophilic  and
hydrophilic drugs, containing natural lipids dispersed in water or in the aqueous surfac‐
tant solution [156].
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Mannose-conjugated SLNs were successfully used to selectively deliver rifabutin,  isonia‐
zid,  and  pyrazinamide  to  alveolar  and  lymphatic  tissues  [157].  Stearic  acid  SLN  im‐
proved the activity of rifampicin,  isoniazid, and pyrazinamide against M. tuberculosis  by
increasing the residence time and the drug bioavailability while decreasing the administra‐
tion frequency [158].
Nanosuspensions could be used for nebulization procedures for delivering drugs poorly
soluble in the lung secretions [159], as already proved by the antitubercular drugs (rifampicin,
isoniazid, and pyrazinamide) incorporated into various formulations of solid lipid particles
ranging from 1.1 to 2.1 µm and nebulized to guinea pigs [160].
4.5. Fullerenes
Fullerenes are a new form of carbon, with hollow sphere, ellipsoid, or tube size. The cationic
fullerene derivatives bearing a substituted-quinazolin-4(3H)-one moiety as a side arm were
reported to have a very good inhibitory potential on M. tuberculosis [161].
4.6. Dendrimers
Mannosylated dendrimers proved to be an efficient drug delivery system for rifampicin in a
rat alveolar macrophages, the sustained release taking place in a pH-dependent manner [162].
The mannosylated fifth-generation poly(propyleneimine) dendrimer nanocarriers proved to
be very efficient for the intracellular uptake of lamivudine, a nucleoside/nucleotide reverse
transcriptase inhibitor, and the reduction of the HIV-1 viral load in the infected MT2 cells [163].
Pegylated lysine-based copolymeric dendrimer improved the proved anti-P. falciparum of
artemether drug, as revealed by the increased drug stability, enhanced solubility, and pro‐
longed drug circulation half-life [164].
A  fourth-generation  hydroxyl-terminated  poly(amidoamine)  (PAMAM)  dendrimer  was
used  as  the  intracellular  vehicle  of  azithromycin  for  the  treatment  of  chlamydial  inclu‐
sions, proving to be more efficient than the free drug with a sustained effect lasting for 24–
48 h post-infection [165].
4.7. Zeolites
Zeolites are crystalline materials with frameworks comprising Si, Al, and O [166]. The zeolites
possess nanochannels and cages of regular dimensions [167]. The nanochannels (pores) of
zeolites are open allowing the diffusion of therapeutic agents from the exterior to the interior
of the zeolites. These networks exhibit a large specific surface area and a good stability in
different environments [167].
Mesoporous silica nanoparticles proved to increase the efficiency of the rifampin and isoniazid
against M. tuberculosis infecting the THP-1 cells [168].
The capability of porous sol-gel processed silica as a carrier for gentamicin has been demon‐
strated, showing a significantly higher rate of bacterial clearance from organs than did the free
drug [169].




Erythrocytes have a great the potential to provide an effective therapy against intracellular
pathogens. Amikacin encapsulation in human carrier erythrocytes demonstrated a slow and
sustained release from the loaded carrier till 48 h, suggesting the potential use of the erythro‐
cytes as a slow release system for antibiotics [170].
5. Conclusion
In the last years, there was an important progress in improving the drug delivery systems for
fighting intracellular bacterial infections. The proposed solutions led to decreased toxicity,
improved bioavailability, and prolonged and sustained release associated with reduced
frequency of administration and enhanced antimicrobial activity. However, the design of the
optimal drug carrier for the intracellular release of different antibiotics should rely on the
elucidation of the intracellular kinetics (accumulation, degradation, and distribution in
different intracellular compartments and activities) of the respective drugs.
The most promising results have been obtained by using natural or synthetic polymers and
liposomes and other lipid formulation carriers, whose efficiency has been demonstrated by in
vitro and in vivo experimental studies, as well as in clinical trials, and which could therefore
represent efficient strategies for fighting severe microbial infections produced by facultative
or obligate intracellular microorganisms as well as for viral infections.
Author details
Mariana Carmen Chifiriuc1,2, Alina Maria Holban1,2,3, Carmen Curutiu1,2, Lia-Mara Ditu1,
Grigore Mihaescu1, Alexandra Elena Oprea3, Alexandru Mihai Grumezescu3* and
Veronica Lazar1
*Address all correspondence to: grumezescu@yahoo.com
1 Microbiology Immunology Department, Faculty of Biology, University of Bucharest,
Bucharest, Romania
2 Research Institute of the University of Bucharest–ICUB, Life, Environmental and Earth
Sciences, Bucharest, Romania
3 Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of
Applied Chemistry and Material Science, University Politehnica of Bucharest, Bucharest,
Romania
Smart Drug Delivery System328
References
[1] Salouti M, Ahangari A. Nanoparticle Based Drug Delivery Systems for Treatment of
Infectious Diseases. 2014. 2014-07-25.
[2] Antibiotic Resistance: Implications for Global Health and Novel Intervention Strat‐
egies: Workshop Summary. Washington, DC: The National Academies Press. 2010.
496 p.
[3] Todar K. Web Review of Todar’s Online Textbook of Bacteriology. http://wwwtext‐
bookofbacteriologynet/Rickettsiahtml. 2009.
[4] Wilson JW, Schurr MJ, LeBlanc CL, Ramamurthy R, Buchanan KL, Nickerson CA.
Mechanisms of bacterial pathogenicity. Postgraduate Medical Journal. 2002 April 1,
2002;78(918):216–24.
[5] Chifiriuc MC, Lixandru M, Iordache C, Bleotu C, Larion C, Olguta D, et al. Internali‐
zation of Staphylococcus aureus and Pseudomonas aeruginosa bacterial cells by non-
phagocytic, epithelial human cells. Romanian Biotechnological Letters. 2008;13(2).
[6] Bleotu C, Chifiriuc MC, Dracea, O., Iordache C, Delcaru C, Lazar V. In vitro modula‐
tion of adherence and invasion ability of enteroinvasive Escherichia Coli by different
viruses. International Journal of Applied Biology and Pharmaceutical Technology.
2010:1359–63.
[7] Chifiriuc MC, Mihaescu G, Lazar V. Medical Microbiology and Virology. University
of Bucharest Publishing House. 2011;ISBN 978-973-737-985-6579.61.
[8] Mihaescu G, Chifiriuc C, Ditu L. General microbiology University of Bucharest Pub‐
lishing House. 2007;ISBN-9789737372689:552.
[9] Chifiriuc MC, Bleotu C, Pelinescu DR, Lazar V, Ditu LM, Vassu T, et al. Patterns of
colonization and immune response elicited from interactions between enteropatho‐
genic bacteria, epithelial cells and probiotic fractions. International Journal of Medi‐
cine and Biomedical Research. 2010;1(4):47–57.
[10] Madigan M, Martinko J, J. P. Brock’s Biology of Microorganisms. 8th edition. New
Jersey: Prentice Hall. 1997.
[11] Nizet V, Esko JD. Bacterial and Viral Infections. Essentials of Glycobiology. CSH
Press. 2009.
[12] Galan JE, Wolf-Watz H. Protein delivery into eukaryotic cells by type III secretion
machines. Nature. 2006;444:567–73.
[13] Chifiriuc MC, Bloetu C, Sokolov D, Mihaescu GLV. Host immune response to Chla‐
mydia infection. In: Mares M, editor. The Book Chlamydia. Intech Open Access.
2011;ISBN 978-953-51-0470-4.
Antibiotic Drug Delivery Systems for the Intracellular Targeting of Bacterial Pathogens
http://dx.doi.org/10.5772/61327
329
[14] Weinrauch Y, Zychlinsky A. The induction of apoptosis by bacterial pathogens. An‐
nual Review of Microbiology. 1999;53(1):155–87. PubMed PMID: 10547689.
[15] Grassme H, Kirschnek S, Riethmueller J, Riehle A, von Kurthy G, Lang F, et al. CD95/
CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa.
Science. 2000 Oct 20;290(5491):527–30. PubMed PMID: 11039936. Epub 2000/10/20.
eng.
[16] Iordache C, Bleotu C, Holban A, Lixandru M, Cotar A, Lazar V, et al. Differential ef‐
fects on caspase mediated apoptosis of hela cells induced by different Pseudomonas
aeruginosa culture fractions. International Journal of Applied Biology and Pharma‐
ceutical Technology. 2011;2(1):132–8.
[17] Mihaescu G, Chifiriuc C, Ditu LM. Imunobiology. University of Bucharest Publica‐
tion House. 2009;ISBN 978-973-737-734-0:572.
[18] Reid CW, Fulton KM, Twine SM. Never take candy from a stranger: the role of the
bacterial glycome in host-pathogen interactions. Future Microbiology. 2010 Feb;5(2):
267–88. PubMed PMID: 20143949. Epub 2010/02/11. eng.
[19] Vimr ER, Kalivoda KA, Deszo EL, Steenbergen SM. Diversity of microbial sialic acid
metabolism. Microbiology and Molecular Biology Reviews. 2004;68(1):132–53.
PubMed PMID: PMC362108.
[20] Lazar V, Balotescu C, Cernat R, Bulai D, Stewart-Tull D. Imunobiologie. Ed Univ din
Bucuresti. 2005;ISBN-973-73-7124-0:250.
[21] Yatsuyanagi J, Saito S, Sato H, Miyajima Y, Amano K-I, Enomoto K. Characterization
of enteropathogenic and enteroaggregative Escherichia coli isolated from diarrheal
outbreaks. Journal of Clinical Microbiology. 2002 07/09/received 09/03/revised 10/21/
accepted;40(1):294-7. PubMed PMID: PMC120118.
[22] Chifiriuc MC, Bleotu C, Marutescu L, Cristea D, Lazar V. The modulation of HeLa
cells secretory patterns by invasive Shigella spp. and enteroinvasive E. coli bacterial
cells and their soluble components. Roumanian Archives of Microbiology and Immu‐
nology. 2010 Jul–Sep;69(3):139–44. PubMed PMID: 21434590. Epub 2011/03/26. eng.
[23] Cristea D, Ceciu S, Chitoiu DT, Bleotu C, Lazar V, Chifiriuc MC. Comparative study
of pathogenicity tests for Shigella spp. and enteroinvasive Escherichia coli strains. Rou‐
manian Archives of Microbiology and Immunology. 2009 Jan–Mar;68(1):44–9.
PubMed PMID: 19507627. Epub 2009/06/11. eng.
[24] de la Torre JC, Borrow P. Chapter 22 Virus-induced alterations in cells. Principles of
Medical Biology1998. p. 365–79.
[25] Israil AM, Balotescu C, Alexandru A, Cojocaru R, Bucurenci N, Chicu V, et al. Char‐
acterization of V. cholerae strain isolated in the Republic of Moldavia between 1995–
1999. Roumanian Biotechnological Letters. 2005;10(6):2441–57.
Smart Drug Delivery System330
[26] Mihaescu G, Chifiriuc (Balotescu) MC. Toxins and other potentially toxic substances.
Romanian Academy Publishing House. 2005;ISBN 973-27-1136-1:364.
[27] Mihaescu G, Chifiriuc MC, L.M. D. Antibiotics and antimicrobial chemotherapeutic
substances. Romanian Academy Publishing House. 2008;ISBN
978-973-27-1573-4.:358.
[28] Brooks GF, Caroll KC, Butel JS, S.A. M. Jawetz, Melnick, & Adelberg’s Medical Mi‐
crobiology, 24th Edition. wwwaccessmedicinecom. 2007.
[29] Collier L, Balows A, Sussman M. Topley and Wilson’s Microbiology and Microbial
Infections, Vol. I, II. 1998.
[30] Beauchamp D, Gourde P, Simard M, Bergeron MG. Subcellular localization of tobra‐
mycin and vancomycin given alone and in combination in proximal tubular cells, de‐
termined by immunogold labeling. Antimicrobial Agents and Chemotherapy.
1992;36(10):2204–10. PubMed PMID: PMC245477.
[31] Van Bambeke F, Snoeck A, Chanteux H, Mingeot-Leclercq M, Tulkens P. Is LY333328
glycopeptide a new cell-associated antibiotic? Comparative studies with vancomycin
and azithromycin in a model of J774 mouse macrophages. 11th European Congress
of Clinical Microbiology and Infectious Diseases Istanbul, Turkey, April 1–4, 2001.
2001.
[32] Pascual A, Tsukayama D, Kovarik J, Gekker G, Peterson P. Uptake and activity of ri‐
fapentine in human peritoneal macrophages and polymorphonuclear leukocytes.
Antimicrobial Agents and Chemotherapy. 1987 Apr;6(2):152–7. PubMed PMID:
2954817. Epub 1987/04/01. eng.
[33] Maderazo EG, Breaux SP, Woronick CL, Quintiliani R, Nightingale CH. High teico‐
planin uptake by human neutrophils. Chemotherapy. 1988;34(3):248–55. PubMed
PMID: 2970950. Epub 1988/01/01. eng.
[34] Van Bambeke F, Carryn S, Seral C, Chanteux H, Tyteca D, Mingeot-Leclercq MP, et
al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic
oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrobial
Agents and Chemotherapy. 2004 Aug;48(8):2853–60. PubMed PMID: 15273091.
PubMed Central PMCID: PMC478544. Epub 2004/07/27. eng.
[35] Jacobs RF, Thompson JW, Kiel DP, Johnson D. Cellular uptake and cell-associated ac‐
tivity of third generation cephalosporins. Pediatric Research. 1986 Sep;20(9):909–12.
PubMed PMID: 3489219. Epub 1986/09/01. eng.
[36] Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Comparative intracel‐
lular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin,
gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant
concentrations. Antimicrobial Agents and Chemotherapy. 2002 Jul;46(7):2095–103.
Antibiotic Drug Delivery Systems for the Intracellular Targeting of Bacterial Pathogens
http://dx.doi.org/10.5772/61327
331
PubMed PMID: 12069960. PubMed Central PMCID: PMC127291. Epub 2002/06/19.
eng.
[37] Wilkinson G. Pharmacokinetics: the dynamics of drugs absorption, distribution and
elimination. In: Hardman JG, Limbird LL, editors. Goodman & Gilman’s the Pharma‐
cological Basis of Therapeutics. New York: McGraw Hill Medical Publishing Divi‐
sion. 2001:3–30.
[38] Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and
resistance. Antimicrobial Agents and Chemotherapy. 1999 Apr;43(4):727–37. PubMed
PMID: 10103173. PubMed Central PMCID: PMC89199. Epub 1999/04/02. eng.
[39] Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their
future. Clinical Microbiology Reviews. 2003;16(3):430–50. PubMed PMID:
PMC164221.
[40] Tulkens P, Trouet A. The uptake and intracellular accumulation of aminoglycoside
antibiotics in lysosomes of cultured rat fibroblasts. Biochemical Pharmacology. 1978
Feb 15;27(4):415–24. PubMed PMID: 24449. Epub 1978/02/15. eng.
[41] Just M, Erdmann G, Habermann E. The renal handling of polybasic drugs. 1. Genta‐
micin and aprotinin in intact animals. Naunyn-Schmiedeberg’s Archives of Pharma‐
cology. 1977 Oct;300(1):57–66. PubMed PMID: 304182. Epub 1977/10/25. eng.
[42] Nagai J, Tanaka H, Nakanishi N, Murakami T, Takano M. Role of megalin in renal
handling of aminoglycosides. American Journal of Physiology. Renal Physiology.
2001 Aug;281(2):F337–44. PubMed PMID: 11457726. Epub 2001/07/18. eng.
[43] Sastrasinh M, Knauss TC, Weinberg JM, Humes HD. Identification of the aminogly‐
coside binding site in rat renal brush border membranes. Journal of Pharmacology
and Experimental Therapeutics. 1982 Aug;222(2):350–8. PubMed PMID: 7097555.
Epub 1982/08/01. eng.
[44] Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular
biology, and epidemiology of bacterial resistance. Microbiology and Molecular Biolo‐
gy Reviews. 2001 Jun;65(2):232–60; second page, table of contents. PubMed PMID:
11381101. PubMed Central PMCID: PMC99026. Epub 2001/05/31. eng.
[45] Coates TD, Torres M, Harman J, Williams V. Localization of chlorotetracycline fluo‐
rescence in human polymorphonuclear neutrophils. Blood. 1987 Apr;69(4):1146–52.
PubMed PMID: 3828534. Epub 1987/04/01. eng.
[46] Carlier MB, Garcia-Luque I, Montenez JP, Tulkens PM, Piret J. Accumulation, release
and subcellular localization of azithromycin in phagocytic and non-phagocytic cells
in culture. International Journal of Tissue Reactions. 1994;16(5–6):211–20. PubMed
PMID: 7558665. Epub 1994/01/01. eng.
[47] Van Bambeke F, Gerbaux C, Michot JM, d’Yvoire MB, Montenez JP, Tulkens PM. Ly‐
sosomal alterations induced in cultured rat fibroblasts by long-term exposure to low
Smart Drug Delivery System332
concentrations of azithromycin. Journal of Antimicrobial Chemotherapy. 1998 Dec;
42(6):761–7. PubMed PMID: 10052900. Epub 1999/03/03. eng.
[48] Ackermann G, Tang YJ, Kueper R, Heisig P, Rodloff AC, Silva J, Jr., et al. Resistance
to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations
in gyrA. Antimicrobial Agents and Chemotherapy. 2001 Aug;45(8):2348–53. PubMed
PMID: 11451695. PubMed Central PMCID: PMC90652. Epub 2001/07/14. eng.
[49] Vester B, Douthwaite S. Macrolide resistance conferred by base substitutions in 23S
rRNA. Antimicrobial Agents and Chemotherapy. 2001;45(1):1–12. PubMed PMID:
PMC90232.
[50] Pascual A, Ballesta S, Garcia I, Perea EJ. Uptake and intracellular activity of linezolid
in human phagocytes and nonphagocytic cells. Antimicrobial Agents and Chemo‐
therapy. 2002 Dec;46(12):4013–5. PubMed PMID: 12435714. PubMed Central PMCID:
PMC132792. Epub 2002/11/19. eng.
[51] Wistreich AG. Microbiology Laboratory Fundamentals and Applications (Hardcov‐
er). 1996.
[52] Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clinical Microbiolo‐
gy Reviews. 1989;2(4):378–424. PubMed PMID: PMC358131.
[53] Hoger PH, Vosbeck K, Seger R, Hitzig WH. Uptake, intracellular activity, and influ‐
ence of rifampin on normal function of polymorphonuclear leukocytes. Antimicrobi‐
al Agents and Chemotherapy. 1985 Nov;28(5):667–74. PubMed PMID: 3004324.
PubMed Central PMCID: PMC176354. Epub 1985/11/01. eng.
[54] Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic in‐
sights. Clinical Microbiology Reviews. 1995 Oct;8(4):496–514. PubMed PMID:
8665467. PubMed Central PMCID: PMC172873. Epub 1995/10/01. eng.
[55] Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM.
Intracellular pharmacodynamics of antibiotics. Infectious Disease Clinics of North
America. 2003 Sep;17(3):615–34. PubMed PMID: 14711080. Epub 2004/01/09. eng.
[56] Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al. Contin‐
uous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind,
randomized controlled trial. Clinical Infectious Diseases. 2013 Jan;56(2):236–44.
PubMed PMID: 23074313. Epub 2012/10/18. eng.
[57] Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithro‐
mycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activi‐
ties against intracellular Staphylococcus aureus in mouse J774 macrophages.
Antimicrobial Agents and Chemotherapy. 2003 Jul;47(7):2283–92. PubMed PMID:
12821480. PubMed Central PMCID: PMC161849. Epub 2003/06/25. eng.
Antibiotic Drug Delivery Systems for the Intracellular Targeting of Bacterial Pathogens
http://dx.doi.org/10.5772/61327
333
[58] Abed N, Couvreur P. Nanocarriers for antibiotics: a promising solution to treat intra‐
cellular bacterial infections. International Journal of Antimicrobial Agents. 2014 Jun;
43(6):485–96. PubMed PMID: 24721232. Epub 2014/04/12. eng.
[59] Singh R, Smitha MS, Singh SP. The role of nanotechnology in combating multi-drug
resistant bacteria. Journal of Nanoscience and Nanotechnology. 2014 Jul;14(7):4745–
56. PubMed PMID: 24757944. Epub 2014/04/25. eng.
[60] Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial
resistance. Advanced Drug Delivery Reviews. 2013 Nov;65(13–14):1803–15. PubMed
PMID: 23892192. Epub 2013/07/31. eng.
[61] Zhang L, Pornpattananangku D, Hu CM, Huang CM. Development of nanoparticles
for antimicrobial drug delivery. Current Medicinal Chemistry. 2010;17(6):585–94.
PubMed PMID: 20015030. Epub 2009/12/18. eng.
[62] Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics us‐
ing liposomes and nanoparticles: research and applications. International Journal of
Antimicrobial Agents. 2000 Jan;13(3):155–68. PubMed PMID: 10724019. Epub
2000/03/21. eng.
[63] Briones E, Colino CI, Lanao JM. Delivery systems to increase the selectivity of antibi‐
otics in phagocytic cells. Journal of Controlled Release. 2008 Feb 11;125(3):210–27.
PubMed PMID: 18077047. Epub 2007/12/14. eng.
[64] Huh AJ, Kwon YJ. “Nanoantibiotics”: a new paradigm for treating infectious diseas‐
es using nanomaterials in the antibiotics resistant era. Journal of Controlled Release.
2011 Dec 10;156(2):128–45. PubMed PMID: 21763369. Epub 2011/07/19. eng.
[65] Rawat M, Singh D, Saraf S, Saraf S. Nanocarriers: promising vehicle for bioactive
drugs. Biological and Pharmaceutical Bulletin. 2006 Sep;29(9):1790–8. PubMed PMID:
16946487. Epub 2006/09/02. eng.
[66] Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site
directed in-vivo delivery of drugs and vaccines. Journal of Nanobiotechnology.
2011;9:55. PubMed PMID: 22123084. PubMed Central PMCID: PMC3238292. Epub
2011/11/30. eng.
[67] Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug
delivery systems. Colloids and Surfaces B: Biointerfaces. 2010 1/1/;75(1):1–18.
[68] Maham A, Tang Z, Wu H, Wang J, Lin Y. Protein-based nanomedicine platforms for
drug delivery. Small (Weinheim an der Bergstrasse, Germany). 2009 Aug 3;5(15):
1706–21. PubMed PMID: 19572330. Epub 2009/07/03. eng.
[69] Kanokpanont S, Damrongsakkul S, Ratanavaraporn J, Aramwit P. An innovative bi-
layered wound dressing made of silk and gelatin for accelerated wound healing. In‐
ternational Journal of Pharmaceutics. 2012 Oct 15;436(1–2):141–53. PubMed PMID:
22771972. Epub 2012/07/10. eng.
Smart Drug Delivery System334
[70] Kuehn C, Graf K, Mashaqi B, Pichlmaier M, Heuer W, Hilfiker A, et al. Prevention of
early vascular graft infection using regional antibiotic release. Journal of Surgical Re‐
search. 2010 Nov;164(1):e185–91. PubMed PMID: 20828762. Epub 2010/09/11. eng.
[71] Hou T, Xu J, Li Q, Feng J, Zen L. In vitro evaluation of a fibrin gel antibiotic delivery
system containing mesenchymal stem cells and vancomycin alginate beads for treat‐
ing bone infections and facilitating bone formation. Tissue Engineering Part A. 2008
Jul;14(7):1173–82. PubMed PMID: 18593356. Epub 2008/07/03. eng.
[72] Portilla-Arias JA, Camargo B, Garcia-Alvarez M, de Ilarduya AM, Munoz-Guerra S.
Nanoparticles made of microbial poly(gamma-glutamate)s for encapsulation and de‐
livery of drugs and proteins. Journal of Biomaterials Science, Polymer Edition.
2009;20(7–8):1065–79. PubMed PMID: 19454169. Epub 2009/05/21. eng.
[73] Okamoto S, Matsuura M, Akagi T, Akashi M, Tanimoto T, Ishikawa T, et al.
Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus
hemagglutinin vaccine protects against influenza virus infection in mice. Vaccine.
2009 Sep 25;27(42):5896–905. PubMed PMID: 19647814. Epub 2009/08/04. eng.
[74] Matsuo K, Ishii Y, Matsuo K, Yoshinaga T, Akashi M, Mukai Y, et al. The utility of
poly(gamma-glutamic acid) nanoparticles as antigen delivery carriers in dendritic
cell-based cancer immunotherapy. Biological and Pharmaceutical Bulletin.
2010;33(12):2003–7. PubMed PMID: 21139241. Epub 2010/12/09. eng.
[75] Takehara M, Hibino A, Saimura M, Hirohara H. High-yield production of short
chain length poly(epsilon-L-lysine) consisting of 5–20 residues by Streptomyces aureo‐
faciens, and its antimicrobial activity. Biotechnology Letters. 2010 Sep;32(9):1299–303.
PubMed PMID: 20464451. Epub 2010/05/14. eng.
[76] Couffin-Hoarau AC, Aubertin AM, Boustta M, Schmidt S, Fehrentz JA, Martinez J, et
al. Peptide-poly(L-lysine citramide) conjugates and their in vitro anti-HIV behavior.
Biomacromolecules. 2009 Apr 13;10(4):865–76. PubMed PMID: 19296658. Epub
2009/03/20. eng.
[77] Ravi Kumar MNV. A review of chitin and chitosan applications. Reactive and Func‐
tional Polymers. 2000 11//;46(1):1–27.
[78] Hench LL. Biomaterials: a forecast for the future. Biomaterials. 1998 Aug;19(16):1419–
23. PubMed PMID: 9794512. Epub 1998/10/30. eng.
[79] Khoushab F, Yamabhai M. Chitin Research Revisited. Marine Drugs. 2010 06/28
05/02/received 05/24/revised 05/08/accepted;8(7):1988–2012. PubMed PMID:
PMC2920538.
[80] Jain KK. Drug delivery systems—an overview. Methods in Molecular Biology (Clif‐
ton, NJ). 2008;437:1–50. PubMed PMID: 18369961. Epub 2008/03/29. eng.
[81] Bajpai AK, Shukla SK, Bhanu S, Kankane S. Responsive polymers in controlled drug
delivery. Progress in Polymer Science. 2008 11//;33(11):1088–118.
Antibiotic Drug Delivery Systems for the Intracellular Targeting of Bacterial Pathogens
http://dx.doi.org/10.5772/61327
335
[82] Chifiriuc MC, Grumezescu AM, Grumezescu V, Bezirtzoglou E, Lazar V, Bolocan A.
Biomedical applications of natural polymers for drug delivery. Current Organic
Chemistry. 2014;18(2):152–64.
[83] Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, et al. Drug delivery
systems: an updated review. International Journal of Pharmaceutical Investigation.
2012 Jan;2(1):2–11. PubMed PMID: 23071954. PubMed Central PMCID: PMC3465154.
Epub 2012/10/17. eng.
[84] Schmaljohann D. Thermo- and pH-responsive polymers in drug delivery. Advanced
Drug Delivery Reviews. 2006 Dec 30;58(15):1655–70. PubMed PMID: 17125884. Epub
2006/11/28. eng.
[85] von Burkersroda F, Schedl L, Gopferich A. Why degradable polymers undergo sur‐
face erosion or bulk erosion. Biomaterials. 2002 Nov;23(21):4221–31. PubMed PMID:
12194525. Epub 2002/08/27. eng.
[86] Keraliya RA, Patel C, Patel P, Keraliya V, Soni TG, Patel RC, et al. Osmotic Drug De‐
livery System as a Part of Modified Release Dosage Form. ISRN Pharmaceutics. 2012
07/17 03/09/received 05/08/accepted;2012:528079. PubMed PMID: PMC3407637.
[87] Urbina MC, Zinoveva S, Miller T, Sabliov CM, Monroe WT, Kumar CSSR. Investiga‐
tion of magnetic nanoparticle−polymer composites for multiple-controlled drug de‐
livery. Journal of Physical Chemistry C. 2008 2008/07/01;112(30):11102–8.
[88] Mano JF. Stimuli-responsive polymeric systems for biomedical applications. Ad‐
vanced Engineering Materials. 2008;10(6):515–27.
[89] Qiu J, Charleux B, Matyjaszewski K. Controlled/living radical polymerization in
aqueous media: homogeneous and heterogeneous systems. Progress in Polymer Sci‐
ence. 2001 12//;26(10):2083–134.
[90] Kingsley JD, Dou H, Morehead J, Rabinow B, Gendelman HE, Destache CJ. Nano‐
technology: a focus on nanoparticles as a drug delivery system. Journal of Neuroim‐
mune Pharmacology. 2006 Sep;1(3):340–50. PubMed PMID: 18040810. Epub
2007/11/28. eng.
[91] Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for
preparation of drug-loaded polymeric nanoparticles. Nanomedicine: Nanotechnolo‐
gy, Biology, and Medicine. 2006 Mar;2(1):8–21. PubMed PMID: 17292111. Epub
2007/02/13. eng.
[92] Lee LY, Wang CH, Smith KA. Supercritical antisolvent production of biodegradable
micro- and nanoparticles for controlled delivery of paclitaxel. Journal of Controlled
Release. 2008 Jan 22;125(2):96–106. PubMed PMID: 18054107. Epub 2007/12/07. eng.
[93] Thiele L, Diederichs JE, Reszka R, Merkle HP, Walter E. Competitive adsorption of
serum proteins at microparticles affects phagocytosis by dendritic cells. Biomaterials.
2003 Apr;24(8):1409–18. PubMed PMID: 12527282. Epub 2003/01/16. eng.
Smart Drug Delivery System336
[94] Ravi Kumar MN. Nano and microparticles as controlled drug delivery devices. Jour‐
nal of Pharmacy and Pharmaceutical Sciences. 2000 May–Aug;3(2):234–58. PubMed
PMID: 10994037. Epub 2000/09/20. eng.
[95] Date AA, Joshi MD, Patravale VB. Parasitic diseases: liposomes and polymeric nano‐
particles versus lipid nanoparticles. Advanced Drug Delivery Reviews. 2007 Jul
10;59(6):505–21. PubMed PMID: 17574295. Epub 2007/06/19. eng.
[96] Ahmad Z, Pandey R, Sharma S, Khuller GK. Alginate nanoparticles as antituberculo‐
sis drug carriers: formulation development, pharmacokinetics and therapeutic poten‐
tial. Indian Journal of Chest Diseases and Allied Sciences. 2006 Jul–Sep;48(3):171–6.
PubMed PMID: 18610673. Epub 2008/07/10. eng.
[97] Nagpal K, Singh SK, Mishra DN. Chitosan nanoparticles: a promising system in nov‐
el drug delivery. Chemical and Pharmaceutical Bulletin. 2010 Nov;58(11):1423–30.
PubMed PMID: 21048331. Epub 2010/11/05. eng.
[98] Huh KM, Lee SC, Cho YW, Lee J, Jeong JH, Park K. Hydrotropic polymer micelle
system for delivery of paclitaxel. Journal of Controlled Release. 2005 Jan 3;101(1–3):
59–68. PubMed PMID: 15588894. Epub 2004/12/14. eng.
[99] Bertesteanu S, Chifiriuc MC, Grumezescu AM, Printza AG, Marie-Paule T, Grume‐
zescu V, et al. Biomedical applications of synthetic, biodegradable polymers for the
development of anti-infective strategies. Current Medicinal Chemistry. 2014;21(29):
3383–90. PubMed PMID: 24606501. Epub 2014/03/13. eng.
[100] Hornig S, Bunjes H, Heinze T. Preparation and characterization of nanoparticles
based on dextran-drug conjugates. Journal of Colloid and Interface Science. 2009 Oct
1;338(1):56–62. PubMed PMID: 19635622. Epub 2009/07/29. eng.
[101] Roseeuw E, Coessens V, Balazuc A-M, Lagranderie M, Chavarot P, Pessina A, et al.
Synthesis, degradation, and antimicrobial properties of targeted macromolecular
prodrugs of norfloxacin. Antimicrobial Agents and Chemotherapy. 2003 12/13/
received 04/14/revised 08/11/accepted;47(11):3435–41. PubMed PMID: PMC253810.
[102] Jiang D, Salem AK. Optimized dextran-polyethylenimine conjugates are efficient
non-viral vectors with reduced cytotoxicity when used in serum containing environ‐
ments. International Journal of Pharmaceutics. 2012 May 1;427(1):71–9. PubMed
PMID: 22037445. PubMed Central PMCID: PMC3295901. Epub 2011/11/01. eng.
[103] Gnanadhas DP, Ben Thomas M, Elango M, Raichur AM, Chakravortty D. Chitosan-
dextran sulphate nanocapsule drug delivery system as an effective therapeutic
against intraphagosomal pathogen Salmonella. Journal of Antimicrobial Chemothera‐
py. 2013 Nov;68(11):2576–86. PubMed PMID: 23798672. Epub 2013/06/27. eng.
[104] De Paula EE, De Sousa FB, Da Silva JC, Fernandes FR, Melo MN, Frezard F, et al. In‐
sights into the multi-equilibrium, superstructure system based on beta-cyclodextrin
Antibiotic Drug Delivery Systems for the Intracellular Targeting of Bacterial Pathogens
http://dx.doi.org/10.5772/61327
337
and a highly water soluble guest. International Journal of Pharmaceutics. 2012 Dec
15;439(1–2):207–15. PubMed PMID: 23022296. Epub 2012/10/02. eng.
[105] Jain A, Gupta Y, Jain SK. Perspectives of biodegradable natural polysaccharides for
site-specific drug delivery to the colon. Journal of pharmacy & pharmaceutical scien‐
ces: a publication of the Canadian Society for Pharmaceutical Sciences, Societe Cana‐
dienne des Sciences Pharmaceutiques. 2007;10(1):86–128. PubMed PMID: 17498397.
Epub 2007/05/15. eng.
[106] Farazuddin M, Chauhan A, Khan RM, Owais M. Amoxicillin-bearing microparticles:
potential in the treatment of Listeria monocytogenes infection in Swiss albino mice. Bio‐
science Reports. 2011 Aug;31(4):265–72. PubMed PMID: 20687896. Epub 2010/08/07.
eng.
[107] Heijink A, Yaszemski MJ, Patel R, Rouse MS, Lewallen DG, Hanssen AD. Local anti‐
biotic delivery with OsteoSet, DBX, and Collagraft. Clinical Orthopaedics and Relat‐
ed Research. 2006 Oct;451:29–33. PubMed PMID: 16906070. Epub 2006/08/15. eng.
[108] Smitha KT, Nisha N, Maya S, Biswas R, Jayakumar R. Delivery of rifampicin-chitin
nanoparticles into the intracellular compartment of polymorphonuclear leukocytes.
International Journal of Biological Macromolecules. 2015 Mar;74:36–43. PubMed
PMID: 25475841. Epub 2014/12/06. eng.
[109] Puoci F, Cirillo G, Curcio M, Parisi OI, Iemma F, Picci N. Molecularly imprinted pol‐
ymers in drug delivery: state of art and future perspectives. Expert Opinion on Drug
Delivery. 2011 Oct;8(10):1379–93. PubMed PMID: 21933031. Epub 2011/09/22. eng.
[110] Sah H, Thoma LA, Desu HR, Sah E, Wood GC. Concepts and practices used to devel‐
op functional PLGA-based nanoparticulate systems. International Journal of Nano‐
medicine. 2013;8:747–65. PubMed PMID: 23459088. PubMed Central PMCID:
PMC3582541. Epub 2013/03/06. eng.
[111] Kaditi E, Mountrichas G, Pispas S, Demetzos C. Block copolymers for drug delivery
nano systems (DDnSs). Current Medicinal Chemistry. 2012;19(29):5088–100. PubMed
PMID: 22963634. Epub 2012/09/12. eng.
[112] Kluin OS, van der Mei HC, Busscher HJ, Neut D. Biodegradable vs non-biodegrada‐
ble antibiotic delivery devices in the treatment of osteomyelitis. Expert Opinion on
Drug Delivery. 2013 Mar;10(3):341–51. PubMed PMID: 23289645. Epub 2013/01/08.
eng.
[113] Ulery BD, Nair LS, Laurencin CT. Biomedical applications of biodegradable poly‐
mers. Journal of Polymer Science Part B: Polymer Physics. 2011;49(12):832–64.
[114] Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nano‐
particles: an overview of biomedical applications. Journal of Controlled Release. 2012
Jul 20;161(2):505–22. PubMed PMID: 22353619. Epub 2012/02/23. eng.
[115] Farazuddin M, Alam M, Khan AA, Khan N, Parvez S, Dutt GU, et al. Efficacy of
amoxicillin bearing microsphere formulation in treatment of Listeria monocytogenes
Smart Drug Delivery System338
infection in Swiss albino mice. Journal of Drug Targeting. 2010 Jan;18(1):45–52.
PubMed PMID: 19624287. Epub 2009/07/25. eng.
[116] Malathi S, Balasubramanian S. Synthesis of biodegradable polymeric nanoparticles
and their controlled drug delivery for tuberculosis. Journal of Biomedical Nanotech‐
nology. 2011 Feb;7(1):150–1. PubMed PMID: 21485846. Epub 2011/04/14. eng.
[117] Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-
co-glycolide) nanoparticle-based inhalable sustained drug delivery system for exper‐
imental tuberculosis. Journal of Antimicrobial Chemotherapy. 2003 Dec;52(6):981–6.
PubMed PMID: 14613962. Epub 2003/11/14. eng.
[118] Skidan IN, Gel’perina SE, Severin SE, Guliaev AE. [Enhanced activity of rifampicin
loaded with polybutyl cyanoacrylate nanoparticles in relation to intracellularly local‐
ized bacteria]. Antibiotiki i Khimioterapiia = Antibiotics and Chemoterapy [sic]/
Ministerstvo Meditsinskoi i Mikrobiologicheskoi Promyshlennosti SSSR. 2003;48(1):
23–6. PubMed PMID: 12741319. Epub 2003/05/14. Povyshenie aktivnosti rifampitsina,
assotsiirovannogo s nanochastitsami iz polibutiltsianoakrilata, v otnoshenii bakterii,
lokalizovannykh vnutri kletok. rus.
[119] Fawaz F, Bonini F, Maugein J, Lagueny AM. Ciprofloxacin-loaded polyisobutylcya‐
noacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity. Inter‐
national Journal of Pharmaceutics. 1998 6/15/;168(2):255–9.
[120] Lecaroz C, Gamazo C, Renedo MJ, Blanco-Prieto MJ. Biodegradable micro- and
nanoparticles as long-term delivery vehicles for gentamicin. Journal of Microencap‐
sulation. 2006 Nov;23(7):782–92. PubMed PMID: 17123922. Epub 2006/11/25. eng.
[121] Fattal E, Pecquet S, Couvreur P, Andremont A. Biodegradable microparticles for the
mucosal delivery of antibacterial and dietary antigens. International Journal of Phar‐
maceutics. 2002 Aug 21;242(1–2):15–24. PubMed PMID: 12176221. Epub 2002/08/15.
eng.
[122] Toti US, Guru BR, Hali M, McPharlin CM, Wykes SM, Panyam J, et al. Targeted de‐
livery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles.
Biomaterials. 2011 Sep;32(27):6606–13. PubMed PMID: 21652065. PubMed Central
PMCID: PMC3133877. Epub 2011/06/10. eng.
[123] Imbuluzqueta E, Elizondo E, Gamazo C, Moreno-Calvo E, Veciana J, Ventosa N, et al.
Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular
bacterial infections. Acta Biomaterialia. 2011 Apr;7(4):1599–608. PubMed PMID:
21115143. Epub 2010/12/01. eng.
[124] Jhunjhunwala S, Raimondi G, Thomson AW, Little SR. Delivery of rapamycin to den‐
dritic cells using degradable microparticles. Journal of Controlled Release. 2009 Feb
10;133(3):191–7. PubMed PMID: 19000726. PubMed Central PMCID: PMC2925512.
Epub 2008/11/13. eng.
Antibiotic Drug Delivery Systems for the Intracellular Targeting of Bacterial Pathogens
http://dx.doi.org/10.5772/61327
339
[125] Gaspar R, Preat V, Opperdoes FR, Roland M. Macrophage activation by polymeric
nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania do‐
novani associated with hydrogen peroxide production. Pharmaceutical Research.
1992 Jun;9(6):782–7. PubMed PMID: 1409361. Epub 1992/06/01. eng.
[126] Fattal E, Youssef M, Couvreur P, Andremont A. Treatment of experimental salmonel‐
losis in mice with ampicillin-bound nanoparticles. Antimicrobial Agents and Chemo‐
therapy. 1989;33(9):1540–3. PubMed PMID: PMC172698.
[127] Forestier F, Gerrier P, Chaumard C, Quero AM, Couvreur P, Labarre C. Effect of
nanoparticle-bound ampicillin on the survival of Listeria monocytogenes in mouse per‐
itoneal macrophages. Journal of Antimicrobial Chemotherapy. 1992 Aug;30(2):173–9.
PubMed PMID: 1399927. Epub 1992/08/01. eng.
[128] Pandey R, Khuller GK. Oral nanoparticle-based antituberculosis drug delivery to the
brain in an experimental model. Journal of Antimicrobial Chemotherapy. 2006 Jun;
57(6):1146–52. PubMed PMID: 16597631. Epub 2006/04/07. eng.
[129] Kuroda K, Caputo GA. Antimicrobial polymers as synthetic mimics of host-defense
peptides. Nanomedicine and Nanobiotechnology. 2013 Jan–Feb;5(1):49–66. PubMed
PMID: 23076870. Epub 2012/10/19. eng.
[130] Palermo EF, Kuroda K. Structural determinants of antimicrobial activity in polymers
which mimic host defense peptides. Applied Microbiology and Biotechnology. 2010
Aug;87(5):1605–15. PubMed PMID: 20563718. Epub 2010/06/22. eng.
[131] Lee S, Yang SC, Heffernan MJ, Taylor WR, Murthy N. Polyketal microparticles: a
new delivery vehicle for superoxide dismutase. Bioconjugate Chemistry. 2007 Jan–
Feb;18(1):4–7. PubMed PMID: 17226951. Epub 2007/01/18. eng.
[132] Seshadri G, Sy JC, Brown M, Dikalov S, Yang SC, Murthy N, et al. The delivery of
superoxide dismutase encapsulated in polyketal microparticles to rat myocardium
and protection from myocardial ischemia-reperfusion injury. Biomaterials. 2010 Feb;
31(6):1372–9. PubMed PMID: 19889454. PubMed Central PMCID: PMC2813932. Epub
2009/11/06. eng.
[133] Kalluru R, Fenaroli F, Westmoreland D, Ulanova L, Maleki A, Roos N, et al. Poly(lac‐
tide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG
infection in macrophages and remain membrane-bound in phago-lysosomes. Journal
of Cell Science. 2013 Jul 15;126(Pt 14):3043–54. PubMed PMID: 23687375. Epub
2013/05/21. eng.
[134] Page-Clisson ME, Pinto-Alphandary H, Chachaty E, Couvreur P, Andremont A.
Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against per‐
sistent Salmonella. Pharmaceutical Research. 1998 Apr;15(4):544–9. PubMed PMID:
9587949. Epub 1998/05/20. eng.
Smart Drug Delivery System340
[135] Discher BM, Won YY, Ege DS, Lee JC, Bates FS, Discher DE, et al. Polymersomes:
tough vesicles made from diblock copolymers. Science. 1999 May 14;284(5417):1143–
6. PubMed PMID: 10325219. Epub 1999/05/15. eng.
[136] Wayakanon K, Thornhill MH, Douglas CW, Lewis AL, Warren NJ, Pinnock A, et al.
Polymersome-mediated intracellular delivery of antibiotics to treat Porphyromonas
gingivalis-infected oral epithelial cells. FASEB Journal. 2013 Nov;27(11):4455–65.
PubMed PMID: 23921377. Epub 2013/08/08. eng.
[137] Coune A. Liposomes as drug delivery system in the treatment of infectious diseases.
Potential applications and clinical experience. Infection. 1988 May–Jun;16(3):141–7.
PubMed PMID: 3042625. Epub 1988/05/01. eng.
[138] Kelly C, Jefferies C, Cryan S-A. Targeted liposomal drug delivery to monocytes and
macrophages. Journal of Drug Delivery. 2011;2011:11.
[139] Khuller GK, Kapur M, Sharma S. Liposome technology for drug delivery against my‐
cobacterial infections. Current Pharmaceutical Design. 2004;10(26):3263–74. PubMed
PMID: 15544514. Epub 2004/11/17. eng.
[140] Yanagihara K. Design of anti-bacterial drug and anti-mycobacterial drug for drug de‐
livery system. Current Pharmaceutical Design. 2002;8(6):475–82. PubMed PMID:
12069384. Epub 2002/06/19. eng.
[141] Gangadharam PR, Ashtekar DA, Ghori N, Goldstein JA, Debs RJ, Duzgunes N. Che‐
motherapeutic potential of free and liposome encapsulated streptomycin against ex‐
perimental Mycobacterium avium complex infections in beige mice. Journal of
Antimicrobial Chemotherapy. 1991 Sep;28(3):425–35. PubMed PMID: 1960123. Epub
1991/09/01. eng.
[142] Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug
delivery. Proceedings of the American Thoracic Society. 2004;1(4):338–44. PubMed
PMID: 16113455. Epub 2005/08/23. eng.
[143] Deol P, Khuller GK. Lung specific stealth liposomes: stability, biodistribution and
toxicity of liposomal antitubercular drugs in mice. Biochimica et Biophysica Acta.
1997 Mar 15;1334(2–3):161–72. PubMed PMID: 9101710. Epub 1997/03/15. eng.
[144] Vitas AI, Díaz R, Gamazo C. Effect of composition and method of preparation of lip‐
osomes on their stability and interaction with murine monocytes infected with Bru‐
cella abortus. Antimicrobial Agents and Chemotherapy. 1996;40(1):146–51. PubMed
PMID: PMC163073.
[145] Fierer J, Hatlen L, Lin JP, Estrella D, Mihalko P, Yau-Young A. Successful treatment
using gentamicin liposomes of Salmonella dublin infections in mice. Antimicrobial
Agents and Chemotherapy. 1990 Feb;34(2):343–8. PubMed PMID: 2327780. PubMed
Central PMCID: PMC171584. Epub 1990/02/01. eng.
[146] Bakker-Woudenberg IA, Lokerse AF, Roerdink FH. Effect of lipid composition on ac‐
tivity of liposome-entrapped ampicillin against intracellular Listeria monocytogenes.
Antibiotic Drug Delivery Systems for the Intracellular Targeting of Bacterial Pathogens
http://dx.doi.org/10.5772/61327
341
Antimicrobial Agents and Chemotherapy. 1988;32(10):1560–4. PubMed PMID:
PMC175919.
[147] Lutwyche P, Cordeiro C, Wiseman DJ, St-Louis M, Uh M, Hope MJ, et al. Intracellu‐
lar delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive lip‐
osomes. Antimicrobial Agents and Chemotherapy. 1998 Oct;42(10):2511–20. PubMed
PMID: 9756749. PubMed Central PMCID: PMC105873. Epub 1998/10/03. eng.
[148] Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug
delivery across the blood–brain barrier. Drug Development and Industrial Pharma‐
cy. 2002 Jan;28(1):1–13. PubMed PMID: 11858519. Epub 2002/02/23. eng.
[149] Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, et al. Targeted nanoparticles
for drug delivery through the blood–brain barrier for Alzheimer’s disease. Journal of
Controlled Release. 2005 Nov 28;108(2–3):193–214. PubMed PMID: 16246446. Epub
2005/10/26. eng.
[150] Kreuter J. Nanoparticulate systems for brain delivery of drugs. Advanced Drug De‐
livery Reviews. 2001 Mar 23;47(1):65–81. PubMed PMID: 11251246. Epub 2001/03/17.
eng.
[151] Seleem MN, Jain N, Pothayee N, Ranjan A, Riffle JS, Sriranganathan N. Targeting
Brucella melitensis with polymeric nanoparticles containing streptomycin and doxycy‐
cline. FEMS Microbiology Letters. 2009 May;294(1):24–31. PubMed PMID: 19493005.
Epub 2009/06/06. eng.
[152] Kadurugamuwa JL, Beveridge TJ. Delivery of the non-membrane-permeative antibi‐
otic gentamicin into mammalian cells by using Shigella flexneri membrane vesicles.
Antimicrobial Agents and Chemotherapy. 1998 Jun;42(6):1476–83. PubMed PMID:
9624497. PubMed Central PMCID: PMC105625. Epub 1998/06/13. eng.
[153] Kamboj S, Saini V, Maggon N, Bala S, Jhawat V. Vesicular drug delivery systems: a
novel approach for drug targeting. International Journal of Drug Delivery. 2013;5(2):
10. Epub 2013-09-17.
[154] Singh G, Dwivedi H, Saraf S, Saraf S. Niosomal delivery of isoniazid: development
and characterization. Tropical Journal of Pharmaceutical Research. 2011;10(2):203–10.
[155] Jain C, Vyas S, VK. D. Niosomal system for delivery of rifampicin to lymphatics. In‐
dian Journal of Pharmaceutical Sciences. 2006;68(5):575–8.
[156] Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation ap‐
proach in drug delivery system. Indian Journal of Pharmaceutical Sciences. 2009 Jul;
71(4):349–58. PubMed PMID: 20502539. PubMed Central PMCID: PMC2865805. Epub
2010/05/27. eng.
[157] Nimje N, Agarwal A, Saraogi GK, Lariya N, Rai G, Agrawal H, et al. Mannosylated
nanoparticulate carriers of rifabutin for alveolar targeting. Journal of Drug Targeting.
2009 Dec;17(10):777–87. PubMed PMID: 19938949. Epub 2009/11/27. eng.
Smart Drug Delivery System342
[158] Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery
system against experimental tuberculosis. Tuberculosis (Edinburgh, Scotland). 2005
Jul;85(4):227–34. PubMed PMID: 15922668. Epub 2005/06/01. eng.
[159] Muller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation,
optimisation and long-term stability. International Journal of Pharmaceutics. 2002
Apr 26;237(1–2):151–61. PubMed PMID: 11955813. Epub 2002/04/17. eng.
[160] Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle in‐
teraction with plasma proteins as it relates to particle biodistribution, biocompatibili‐
ty and therapeutic efficacy. Advanced Drug Delivery Reviews. 2009 Jun 21;61(6):428–
37. PubMed PMID: 19376175. PubMed Central PMCID: PMC3683962. Epub
2009/04/21. eng.
[161] Patel MB, Harikrishnan U, Valand NN, Modi NR, Menon SK. Novel cationic quina‐
zolin-4(3H)-one conjugated fullerene nanoparticles as antimycobacterial and antimi‐
crobial agents. Archiv der Pharmazie. 2013 Mar;346(3):210–20. PubMed PMID:
23359525. Epub 2013/01/30. eng.
[162] Kumar PV, Asthana A, Dutta T, Jain NK. Intracellular macrophage uptake of rifam‐
picin loaded mannosylated dendrimers. Journal of Drug Targeting. 2006 Sep;14(8):
546–56. PubMed PMID: 17050121. Epub 2006/10/20. eng.
[163] Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivudine loaded
mannosylated poly (propyleneimine) dendrimer. Biochimica et Biophysica Acta.
2007 Apr;1770(4):681–6. PubMed PMID: 17276009. Epub 2007/02/06. eng.
[164] Bhadra D, Bhadra S, Jain NK. Pegylated lysine based copolymeric dendritic micelles
for solubilization and delivery of artemether. Journal of Pharmacy and Pharmaceuti‐
cal Sciences. 2005;8(3):467–82. PubMed PMID: 16401394. Epub 2006/01/13. eng.
[165] Mishra MK, Kotta K, Hali M, Wykes S, Gerard HC, Hudson AP, et al. PAMAM den‐
drimer-azithromycin conjugate nanodevices for the treatment of Chlamydia trachoma‐
tis infections. Nanomedicine: Nanotechnology, Biology, and Medicine. 2011 Dec;7(6):
935–44. PubMed PMID: 21658474. Epub 2011/06/11. eng.
[166] Corma A, Garcia H. Supramolecular host–guest systems in zeolites prepared by ship-
in-a-bottle synthesis. European Journal of Inorganic Chemistry. 2004;2004(6):1143–64.
[167] Vilaça N, Amorim R, Machado AF, Parpot P, Pereira MFR, Sardo M, et al. Potentia‐
tion of 5-fluorouracil encapsulated in zeolites as drug delivery systems for in vitro
models of colorectal carcinoma. Colloids and Surfaces B: Biointerfaces. 2013
12/1/;112(0):237–44.
[168] Clemens DL, Lee BY, Xue M, Thomas CR, Meng H, Ferris D, et al. Targeted intracel‐
lular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macro‐
phages via functionalized mesoporous silica nanoparticles. Antimicrobial Agents
Antibiotic Drug Delivery Systems for the Intracellular Targeting of Bacterial Pathogens
http://dx.doi.org/10.5772/61327
343
and Chemotherapy. 2012 May;56(5):2535–45. PubMed PMID: 22354311. PubMed
Central PMCID: PMC3346638. Epub 2012/02/23. eng.
[169] Seleem MN, Munusamy P, Ranjan A, Alqublan H, Pickrell G, Sriranganathan N. Sili‐
ca-antibiotic hybrid nanoparticles for targeting intracellular pathogens. Antimicrobi‐
al Agents and Chemotherapy. 2009 08/10 06/17/received 07/12/revised 08/03/
accepted;53(10):4270–4. PubMed PMID: PMC2764215.
[170] Gutierrez Millan C, Bax BE, Castaneda AZ, Marinero ML, Lanao JM. In vitro studies
of amikacin-loaded human carrier erythrocytes. Translational Research. 2008 Aug;
152(2):59–66. PubMed PMID: 18674740. Epub 2008/08/05. eng.
Smart Drug Delivery System344
